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8INTRODUCTION  
For many athletes, sport is not safe enough without medicines. If they suffer from 
asthma, high blood pressure, or cardiac arrhythmia, sport places their bodies under 
unique stresses, which raise the likelihood of a chronic or catastrophic harm (Savulescu 
et al. 2004).   
During the 19th century, performance-enhancing drug-use among athletes was common. 
Swimmers, distance runners, sprinters, and cyclists used drugs such as caffeine, 
alcohol, nitroglycerine, digitalis, cocaine, strychnine, ether, opium, and heroin in 
attempts to gain a competitive edge over their opponents (Yesalis et al. 2001). Using 
drugs to cheat in sport is not new, but it is becoming more effective (Savulescu et al. 
2004). Drugs are much more effective today than they were in the days of strychnine 
and sheep’s testicles. Studies about anabolic steroids have shown that muscular 
strength could be improved by 5-20% even in doses much lower than those used by 
athletes (Hartgens and Kuipers 2004). The enormous rewards for the winners, the 
effectiveness of the drugs, and the low rate of testing all combine to create a cheating 
game that may be irresistible to some athletes. The lure of success is great. But the 
penalties for cheating are small. 
The medicalization process has also enveloped sport. Central to the medicalization of 
sport has been the development of sports medicine, which is premised on the idea that 
highly-trained athletes have special medical needs and therefore require special medical 
supervision (Waddington 2000). The development of sports medicine has been 
associated with the development of a culture which encourages the treatment not just of 
injured athletes, but also of healthy athletes, with medicines and drugs (Houlihan 1999). 
Indeed, athletes use a variety of medicines to treat injuries, cure illnesses, and obtain a 
competitive edge (Corrigan and Kazlauskas 2003). It is unrealistic to expect athletes to 
insulate themselves from a culture which expects pharmacists and doctors to be able to 
supply medicines for all their ills whether physical or psychological (Waddington 2000).    
All medicines have potential adverse effects that may have deleterious impact on the 
maximum exercise performance of elite athletes. According to several studies, use of 
antiasthmatic medication is more frequent among athletes than in the general population 
(Helenius et al. 1997; Nystad et al. 2000). Apart from these, little is known of the 
medication use in highly-trained athletes (Corrigan and Kazlauskas 2003). Thus far, no 
study has focused on the use of overall medicine intake in a large number of Olympic-
level athletes and compared it with the uptake in the general population. This study was 
performed to assess medication use and attitudes towards doping in highly-trained elite 
athletes. The review of the literature deals with the specific physiological and 
pathophysiological changes in highly-trained athletes. Most commonly used medicines 
and their effects on the athletes and exercise performance are described. The effects of 
exercise on the pharmacokinetics of the drugs are also discussed. As the current study 
is pharmacoepidemiology oriented, the discussion section is more focused on the 
pharmacoepidemiology and prevalence of asthma and allergies in elite athletes. 
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9REVIEW OF THE LITERATURE 
PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL CHANGES IN ELITE 
ATHLETES
Respiratory function 
Sport exercise may increase ventilation up to 200 liters per minute for short periods of 
time in speed and power athletes and for longer periods in endurance athletes (Helenius 
and Haahtela 2000). The upper respiratory tract functions as a physical filter, heat 
exchanger, and humidifier for inhaled air. When the ventilation level exceeds about 30 
liters per minute, a shift occurs from nasal breathing to combined mouth and nasal 
breathing (Anderson and Togias 1995). This shift results in a greater deposition of 
airborne allergens and other inhaled particles into the athlete’s lower airways; in 
addition, incompletely conditioned air may reach the mucous membranes of the lower 
airways (McFadden et al. 1985). The increase in ventilation with dry and cool air leads to 
loss of heat and water from the bronchial mucosa in the attempt to humidify and warm 
the incoming air (Tan and Spector 1998). The loss of heat and moisture produces 
cooling of the airways. The increased amount of ventilation and the lowered temperature 
of inspired air cause bronchoconstriction in susceptible individuals. 
Inhalation of cold air during light exercise increases the number of inflammatory cells in 
the lungs in healthy subjects when compared with exercise in normal temperature (20-
25°C, Larsson et al. 1998). Airway inflammation in elite athletes has been characterized 
in swimmers (Helenius et al. 1998c and 2002), ice hockey players (Lumme et al. 2003) 
and cross-country skiers (Sue-Chu et al. 1998 and 1999; Karjalainen et al. 2000). 
Helenius et al. (2002) showed in their 5-year follow-up study of 42 highly trained 
swimmers that in swimmers who had stopped high-level training, eosinophilic airway 
inflammation, bronchial hyperresponsiveness and asthma attenuated or even 
disappeared. In contrast, airway inflammation was aggravated among swimmers who 
continued intensive training during the 5-year follow-up. The authors concluded that 
symptoms indicating mild asthma result from high swimming activity and are partly 
reversible.
It has been suggested that strong and repeated exposure to airborne allergens causes 
not only bronchial symptoms but also allergic rhinitis (AR) in elite summer-sport athletes 
(Tikkanen and Helenius 1994). Alteration of upper airway function may result in 
alteration of lower airway function.
Asthma and allergies in Olympic athletes 
Of the athletes participating in summer Olympic Games, 4-15% has reported physician 
diagnosed asthma (Table 1). Twenty-two percent of the U.S Olympic athletes who 
9
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participated in 1998 Winter Olympic Games reported physician-diagnosed asthma 
(Weiler and Ryan 2000). In the 1976 and 1980 Olympic Games, 9.7% and 8.5% of the 
Australian Olympic athletes reported asthma in a physical examination (Fitch 1984). 
Allergy was reported by 10% of the athletes in both Olympic Games. 
Prevalence of asthma and allergies in other athlete studies 
Prevalence of asthma has ranged from 4% to 59% in various athlete studies (Table 2). 
The observed large variation is mainly due to different types of training and training 
environments (Helenius 1998d) as discussed in the chapter entitled training environment 
of the athletes. Also differences in the definition and diagnostics of asthma may have had 
some impact on the variation of these results. An especially high prevalence of asthma 
has been found among those athletes competing in endurance events, such as cycling, 
swimming, cross-country skiing, and long-distance running. AR and atopy are more 
common in endurance athletes competing in summer events as compared with control 
subjects (Helenius et al. 1998a), whereas the occurrence of atopy in skiers is similar to in 
control subjects (Sue-Chu et al. 1996).                                                                                   
Cardiovascular 
Sport exercise causes several physiological changes. Some of these changes take 
place during and immediately following the activity. Other changes occur over time as a 
result of a long-term exercise (Lenz et al. 2004).  
During exercise, cardiac output and the distribution of blood changes considerably to 
meet the oxygen demands of working organs and tissues (McArdle et al. 2001). In 
general, blood is shunted away from the central organs (except heart and brain) toward 
the working muscles. During an acute physical activity, both heart rate and stroke 
volume increase. At rest, cardiac output is approximately 5L. Of this, 1.35L (27%), 1.10L 
(22%) and 1.00L (20%) are distributed to the liver, kidneys and muscles, respectively, 
each minute. During strenuous exercise, approximately 0.50L (2%), 0.25L (1%), and 
21.0L (84%) of blood is distributed to the liver, kidneys and muscles, respectively each 
minute.
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Long-term endurance training triggers increases in cardiac mass and structural 
remodelling in many athletes (Maron 2003). This effect may become exaggerated in 
athletes using anabolic steroids increasing the risk of severe cardiac arrhythmias (Stolt 
et al. 1999). The physiologic form of hypertrophy is regarded as a benign adaptation to 
systematic athletic training with no adverse cardiovascular consequences. The resultant 
changes include enlargement and increased volume of the ventricular chambers, 
sometimes accompanied by increased thickness of the left ventricular wall. The 
morphologic adaptations of athlete’s heart may mimic the cardiovascular disease and 
lead to a differential diagnosis that includes hypertrophic and dilated cardiomyopathy 
and arrythmogenic right ventricular cardiomyopathy. Overdiagnosis pathologic 
conditions may, however, lead to unnecessary restrictions, depriving athletes of the 
psychological and monetary benefits of sports. 
Although the overall population of athletes is at generally low risk for sudden death, a 
number of largely congenital but clinically unsuspected cardiovascular diseases have 
been causally linked to sudden death in young trained athletes, usually in association 
with physical exertion. According to autopsy based surveys of athletes in the United 
States, hypertrophic cardiomyopathy has been the single most common cardiovascular 
cause of sudden death accounting for about one third of these events (Maron et al. 
1996).  
Immunologic 
Physical exercise affects the immune system in a highly specific manner influenced by 
mode and duration of exercise, subject characteristics, the environment and numerous 
other factors (Malm 2004). The practice of moderate, regular physical training is 
considered to be associated with a decreased sensitivity to upper respiratory tract 
infections. However, strenuous exercise is followed by temporary functional 
immunodepression (Friman and Wesslen 2000). During that “open window period” the 
sensitivity to upper respiratory tract infections and possibly to other infections is 
potentially increased. The following changes in immune system has been observed after 
prolonged, heavy exercise: high neutrophil and low lymphocyte blood counts induced by 
high plasma cortisol, decreased nasal neutrophil phagocytosis,  decreased IgA-
mediated immune protection at the mucosal surface, decreased nasal mucociliary 
clearance, and decrease in natural killer cell activity (Nieman 2000). This impaired 
immunity may last between 3 and 72 hours depending on the immune measure. The 
infection risk may be amplified when other factors related to immune function are 
present, including exposure to novel pathogens during travel, lack of sleep, severe 
mental stress, malnutrition or weight loss.  
Recently, Malm (2004) concluded in his review article of exercise immunology that due 
to large number of uncontrolled variables in human epidemiological studies conclusive 
evidence for altered infection sensitivity in humans is difficult to obtain. 
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Endocrinological 
Exercise-induced hormonal responses depend on intensity and duration of exercise, 
fitness, gender, age, rest period between sets, and the mode of muscle contraction 
(Kraemer et al. 1990; Vasankari 1994; Durand et al. 2003; Weltman et al. 2006). The 
main anabolic and catabolic hormonal responses to acute physical exercise and training 
in men are presented in Table 3. Acute short-term exercise (intensity >80% of VO2max)
increases serum testosterone concentration in men (Schmid et al. 1982). However, 
basal serum testosterone concentrations are lower in endurance-trained male athletes 
than in control subjects (Hackney et al. 1988 and 1990). Because of menstrual cycle 
and menstrual irregularities endocrinological exercise responses in female athletes are 
more complicated than in males (Consitt et al. 2003). 
Cortisol is the main catabolic hormone that is involved in counteracting the anabolic 
hormone response to exercise (Consitt et al. 2003). An elevated resting cortisol level, 
which causes a decrease in the testosterone to cortisol ratio, has been previously used 
as an indicator of overtraining in athletes (Adlercreutz et al. 1986). Exercise has also 
been shown to be a strong stimulator of catecholamine release (Weltman et al. 2000). 
The catecholamines appear to elevate in direct relation to increasing exercise intensity 
(McMurray et al. 1987).  
TABLE 3. Hormonal responses to acute exercise and training in men (Deschenes et al. 
1991; Vasankari 1994). 
    acute short-term
    physical exercise  
acute prolonged 
physical exercisea
training 
effect
Testosterone ?? ? ??
Growth hormone  ??? ?? ?
Cortisol ??? ? ?
adefined as exercise lasting longer than 2 h. 
? indicates increases in concentration; ? indicates decreases in concentration;  
? indicates no change or equivocal results
Musculoskeletal 
Strenuous exercise places tremendous stress on the musculoskeletal system 
(Almekinders 2002). Breakdown of this system is, to some degree, inevitable during 
regular training. Acute injuries are, of course, obvious examples of breakdown in the 
musculoskeletal system. However, most of the breakdown is less obvious and each 
strenuous exercise most likely causes some breakdown at microscopic level (Leadbetter 
1990). In most cases the body is able to heal this kind of microtrauma before the next 
exercise session. In addition, the musculoskeletal system is able to adapt to the 
mechanical demands by becoming stronger and minimizing any breakdown that occurs. 
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Not only muscle hypertrophy and increased bone density but also increased ligament 
strength has been documented as normal physiological response (Cabaud et al. 1980). 
Stretch-induced muscle injuries or strains, muscle contusions and delayed-onset muscle 
soreness (DOMS) are common muscle problems in athletes (Almekinders 1999). 
Indeed, muscle injuries make up the majority of all sports-related injuries (Kujala et al. 
1995a; Garrett 1990). Although they are generally considered minor injuries, they can 
account for significant disability because of their frequency as well as symptoms. There 
are several causes of muscle injuries (Almekinders 1999). An acute stretch of a muscle 
can cause a partial or even complete tear of the muscle-tendon unit. These injuries are 
usually designated as stretch-induced injuries or muscle strains. A direct, non-
penetrating hit to the muscle is another common mechanism for muscle injuries. Such 
muscle contusions can also cause damage to the structure and function of the muscle.  
Kujala et al. (1995a) analysed the types and severity of acute injuries in some common 
team sport games (soccer, ice hockey, volleyball, basketball) as well as in judo and 
karate in Finland. The data were based on sports injury insurance registry. Karate and 
judo had the highest injury rates followed by ice hockey, soccer, and basketball. All the 
sports studied had higher acute injury rates than reported among endurance athletes 
(Kujala et al. 1995b). Endurance sports may, however, cause the highest rates of stress 
injuries. Sprains, strains, and bruises were the most common types of injury. Non-dental 
fractures accounted only 4.0-10.8% of injuries overall, occurring most often in karate, 
judo, and ice hockey and least often in volleyball. The authors concluded that the 
frequency of acute injuries varies among different sporting events and each sport has a 
specific injury profile. Violent bodily contact between athletes increases the risk of injury.  
Delayed Onset Muscle Soreness  
Following unaccustomed physical activity, a sensation of discomfort, predominantly 
within skeletal muscle, may be experienced in the elite or novice athlete. This DOMS is 
most prevalent at the beginning of the sporting season when athletes are returning to 
training following a period of reduced activity. DOMS is also common when athletes are 
first introduced to certain types of activities regardless of the time of the year. The 
intensity of discomfort increases progressively within the first 24 hours following 
cessation of exercise, peaks between 24 and 72 hours, subsides and eventually 
disappears by 5-7 days post-exercise. DOMS is usually associated with unfamiliar, high-
force muscular work and is precipitated by eccentric actions. Eccentric activity is 
characterized by an elongation of the muscle during simultaneous contraction. 
Particularly, if the athlete is not accustomed to eccentric exercise, lengthening 
contractions evoke a mild inflammatory response within two to three days after the 
exercise. Repeated eccentric muscle contractions can result in pain, stiffness and 
decreased function (Almekinders 1999). DOMS may rather be a physiological 
adaptation to unusual exercise than a true injury. Nevertheless, it may cause disability 
for athletes to perform at maximum level. 
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TRAINING ENVIRONMENT OF THE ATHLETES 
Athletes who participate in summer events are intensively exposed to airborne allergens 
during their training and competitions, whereas winter-sport athletes are exposed to cold 
air (Tikkanen and Helenius 1994). Swimmers are exposed to chlorine derivatives 
(Aggazotti 1993; Potts 1996; Drobnic 1996; Helenius et al. 2002). Competitive swimmers 
inhale and microaspirate large amounts of air immediately above the water surface and 
are thus exposed to chlorine derivatives from swimming pool disinfectants. Inhalation of 
hypotonic liquid may have additive effects (Helenius and Haahtela 2000). Ice-hockey 
players and figure skaters are intensively exposed to cold air and often increased carbon 
monoxide (CO), nitric oxide (NO), and nitric dioxide (NO2) concentrations in ice hockey 
arenas that use ice resurfacers with combustion engines (Pennanen et al. 1997).  
Pennanen et al. (1997) estimated that the highest levels of NO2 were about 20 times the 
World Health Organization health-based air quality guidelines. In skiers (Sue-Chu et al. 
1996; Helenius and Haahtela 2000; Leynaert et al. 2000), the association between atopy, 
respiratory allergy, and asthma has not been demonstrated to be as clear as in summer-
sport athletes (Helenius et al. 1998a and 1998b).  
REFLECTIONS OF THE SOCIETY ON THE MEDICALIZATION OF THE 
SPORT 
The medicalization in society generally has involved growing dependence on 
professionally provided care and on medicines, the medicalization of prevention and 
medicalization of the expectations of lay people regarding health-related issues (Zola 
1972). Improvements in chemical technology –the so-called pharmacological revolution 
from the 1950s and 1960s – which resulted in the development of more potent, more 
selective and less toxic medicines and the growing involvement of sports physicians in 
the medical management of athletes are two key processes that provide the essential 
context for understanding the increase in the medicalization process in sport 
(Waddington 2000). Sports medicine is premised on the idea that highly trained athletes 
have special medical needs and therefore special medical supervision. Houlihan (1999) 
has stressed that the use of performance enhancing drugs needs to be seen in the 
context of an increasingly pill-dependent society and it is unrealistic to expect athletes to 
insulate themselves from a culture which expects pharmacists and doctors to be able to 
supply medicines for all their ills whether physical or psychological. 
Sport is now more competitive and more serious than it used to be (Roberts and Olsen 
1989). Sport is played for high stakes, whether these are economic, political, personal or 
combination of all three. This is another important part of the context for understanding 
the increasing cooperation between athletes and sports physicians in the search for 
medal winning and record-breaking performances. It is also an important part of the 
context for understanding the increasing use of drugs in sport. The greatly increased 
importance of winning has lead many athletes to accept and internalize values 
associated with a culture of risk. This involves generally willingness to continue training 
and competing with pain and injury and, in many cases, to accept the risks associated 
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with the use of drugs, both licit and illicit (Roderick et al. 2000). As the rewards 
associated with winning have increased, the role of sport medicine practitioners in 
maximizing performance has become more important (Hoberman 1992). Elite athletes 
are more and more dependent on increasingly sophisticated systems of medical support 
in their efforts to run faster, to jump higher or to compete more effectively in their sport. 
At the highest level the quality of medical support may make the difference between 
success and failure (Hoberman 1992). 
According to Sutherland and Cressy’s theory of differential association (1974),  the use 
of performance-enhancing drugs cannot be understood as the behaviour of an isolated 
individual, for the use of drugs implies not only a network of relationships between users 
and suppliers, but drug use itself is seen as a process involving learning from, and 
encouragement by, others. 
The development of sports medicine has been associated with the development of a 
culture which encourages the treatment not just of injured athletes, but also of healthy 
athletes with medicines and drugs (Houlihan 1999). European Group on Ethics in 
Science and New Technologies (1999) has also pointed that it is difficult to draw the line 
between the medicalization of the athlete to preserve his/her health and the prescription 
of drugs to enhance performance.  
PHARMACOLOGIC TREATMENT OF ELITE ATHLETES 
Athletes use a variety of non-doping classified medicines to treat injuries, cure illnesses, 
and obtain a competitive edge (Corrigan and Kazlauskas 2003). According to several 
studies, use of antiasthmatic medicines is more frequent among athletes than in the 
general population (Helenius et al. 1997; Nystad et al. 2000).  Apart from studies 
concerning asthma and allergy medication, little is known of the use of medications in 
highly trained athletes (Berglund and Sundgot-Borgen 2001; Corrigan and Kazlauskas 
2003). 
Pharmacologic treatment of asthma and allergies in elite athletes 
Inhaled β2-agonists 
Inhaled β2-agonists are the medicines of choice for the prevention of exercise-induce 
asthma (EIA; Lacroix 1999). They have a rapid onset of action (within 15 minutes), 
produce a prolonged effect (up to 6 hours), and are convenient to use, and side effects 
are generally manageable. When given about 30 minutes before exercise, they prevent 
asthma symptoms in 90% of patients. 
As beta-adrenergic drugs, inhaled β2-agonists act through adenyl cyclase to increase 
intracellular concentrations of cyclic adenosine monophosphate (AMP), which 
modulates contraction and relaxation of bronchial and vascular smooth muscle (Nelson 
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1995). Increased concentrations of cyclic AMP also inhibit the release of mediators from 
mast cells. However, despite their β2-selectivity, drugs such as salbutamol and 
terbutaline sulfate interact with α- and β-1 adrenergic receptors, causing side effects 
such as tachycardia, palpitations, increased wakefulness, and mild tremors. These 
extrapulmonary effects may impair athletic performance especially in events that require 
skilled motor performance (Storms 2003).
Regular treatment with β2-agonists increase airway responsiveness to nonallergic stimuli 
(Kerrebijn et al. a1987, Vathenen et al. 1988), and enhance allergen-induced late 
bronchoconstrictor responses (Cockcroft et al. 1993, Cockcroft et al. 1995, Gauvreau et 
al. 1997). The regular use of β2-agonists in conjunction with allergen exposure may even 
have proinflammatory effects (Gauvreau et al. 1997). Therefore, athletes with asthma 
should not be treated only with inhaled β2-agonists, since they encounter repeatedly air-
borne allergens during training and competition (Helenius 1998d). The loss of the 
bronchoprotective effects of salbutamol against allergens and exercise, when β2-agonist 
is used regularly without corticosteroids, has also been observed (Gibson et al. 1978; 
Cockcroft et al. 1993).  
Longer-acting β2-agonists such as salmeterol and formoterol act for up to 12 hours 
(Anderson et al. 1991; Newnham et al. 1993; Kemp et al. 1994).  For maximal effect 
salmeterol should be taken at least 4 hours before exercise (Schaanning et al. 1996). 
Formoterol has faster onset of action, comparable to salbutamol (Van Noord 1996). 
Long-acting β2-agonists are useful for athletes competing in endurance sports such as 
marathons and triathlons. However, it is important to note that with long-term 
administration of a long-acting β2-agonist, salmeterol, protection against EIA is 
maintained, but the length of time that the medicine remains active after a single dose 
decreases (Nelson et al. 1998). Salmeterol loses some effectiveness after 9 hours. This 
loss of response may be reduced if an inhaled corticosteroid is also being used 
(Pauwles et al. 1997).  
Ferrari et al. (2000) evaluated the efficacy of long-acting β2-agonist, formoterol, in 
preventing EIB in 14 young athletes with a known history of EIB. Formoterol induced 
significant protection against EIB compared with placebo. This protective effect was still 
present 4 hours after administration. Several studies have shown that the use of inhaled 
β2-agonists does not seem to enhance exercise performance in non-asthmatic athletes 
when given in doses required to relieve bronchospasm or prevent EIB (Morton et al. 
1992; Sandsund et al. 1998; Carlsen et al. 2001; Stewart et al. 2002; McKenzie and 
Stewart 2002).  
Recently, the International Olympic Committee (IOC) has restricted the use of inhaled 
β2-agonists in Olympic athletes requiring documentation from any athletes who might 
use them (Anderson et al. 2003). The reasons for these new regulations were: the large 
increase in the number of athletes reporting the need to use inhaled β2-agonist,
misdiagnosis of asthma, under-use of inhaled corticosteroids, and possible tolerance to 
β2-agonists when used daily. 
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Inhaled corticosteroids 
With the recognition that airway inflammation is present even in patients with mild 
asthma, inhaled corticosteroids are the mainstay of treatment for patients who have 
asthma (Barnes 1989 and 1995; Haahtela et al. 1991, 1994 and 2001). Inhaled 
corticosteroids have anti-inflammatory effects on the bronchial mucosa in these patients 
(Djukanovic et al. 1992; Laitinen et al. 1992). By reducing airway inflammation, these 
medications decrease airway responsiveness in adults and children with asthma 
(Barnes 1990). Long-term treatment with inhaled glucocorticosteroids lowers 
responsiveness to various stimuli, including exercise, allowing a higher level of exertion 
before a response is triggered (Barnes 1995; Smith and Labotz 1998). Inhaled 
corticosteroid therapy not only makes the airways less sensitive to spasmogens, but 
also limits the maximal narrowing of the airway in response to a spasmogen (Bel et al. 
1991). The reduction in airway hyperresponsiveness may not be maximal until treatment 
has been given for several months (Barnes 1995). Effective suppression of airway 
inflammation reduces also the need for bronchodilator therapy (Barnes 1989; Haahtela 
et al. 1991). 
Inhaled corticosteroids offer no benefit when used only before exercise; they are not 
effective immediately after administration (Smith and Labotz 1998). They may, however, 
be useful on a long-term basis. In some athletes, at least 4 weeks of inhaled 
corticosteroid use may be effective when combined with inhaled β2-agonists. Inhaled 
corticosteroids are needed in athletes when bronchial symptoms become weekly or 
airway inflammation with bronchial hyperresponsiveness has been observed (Helenius 
and Haahtela 2000; Bonini et al. 2004). Exposure to air-borne allergens often 
necessitate their use early in summer sports athletes.   
Papalia (1996) reported that one week after starting inhaled steroid (budesonide), well-
trained athletes with asthma showed marked reduction in EIB. In a double-blind, 
randomised, parallel group trial on 25 cross-country skiers, Sue-Chu et al. (2000a) 
evaluated the effect of budesonide 400 μg inhaled twice daily for 12 weeks. Seasonal 
bias may have affected this study, since it began in the autumn and ended in the winter. 
Even so, the study failed to show any beneficial effect of an inhaled corticosteroid 
bronchial symptoms, BHR or airway inflammation compared with placebo treatment. 
Leukotriene modifiers 
Leukotrienes are inflammatory mediator products of phospholipid metabolism (Drazen 
et. 1999). Arachidonic acid is the precursor fatty acid that is transformed into the 
leukotrienes by way of the 5-lipoxygenase pathway. Leukotrienes are involved in the 
pathogenesis of asthma and EIB by inducing smooth muscle contraction (Reis et al. 
1997). Leukotrienes are thought to induce a bronchoconstriction response 1,000 times 
greater than that triggered by histamines. Specifically, the cysteinyl leukotrienes 
(leukotrienes C4, D4 and E4), cause bronchoconstriction by increasing eosinophil 
migration (Laitinen et al. 1993; Diamant et al. 1997), mucus production (Piacentini and 
Kaliner 1991), and airway-wall edema (Wasserman et al. 1995)  
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Leukotriene modifiers include the leukotriene-receptor antagonists montelukast and 
zafirlukast and the 5-lipoxygenase inhibitor zileuton (Drazen et. 1999). They appear to 
protect against EIA in many, but not all, patients with chronic asthma. Medicines that 
inhibit the action or formation of leukotrienes may also improve rhinitis, which may be an 
added benefit for patients with asthma (Knapp 1990; Donnelly et al. 1995). The 
leukotriene modifiers offer certain advantages over other EIA medications: they come in 
oral form, have few side effects, and offer 24-hour protection (Leff et al. 1998; Hansen-
Flaschen and Scothland 1998). Most of the reports evaluating the inhibitory effect of 
montelukast on EIA have identified an approximate 50% improvement in post-exercise 
forced expiratory volume in one second (FEV1) after treatment (Reis et al. 1997; Leff et 
al. 1998; Villaran et al. 1999; Melo et al. 2003; Peroni 2002; Rundell et al. 2005). In a 
double-blind, randomised, placebo-controlled study, Leff et al. (1998) observed that 
once-daily treatment with 10 mg of montelukast provided significant protection against 
EIA over a 12-week period. Tolerance to the medication and rebound worsening of lung 
function after discontinuation of treatment were not seen. Rundell et al. (2005) examined 
the effectiveness of a single dose of 10 mg of montelukast after a six minute exercise in 
cold air in 11 physically active subjects with EIB. In this randomised, placebo-controlled, 
double-blind, crossover trial montelukast provided significant protection against 
bronchoconstriction for eight subjects; no protection was afforded for three subjects. 
However, in a double-blind, randomised, crossover trial, in young, male ice hockey 
players (N = 16) Helenius et al. (2004) observed no improvement in airway 
inflammation, pulmonary function, BHR, or daily symptoms after montelukast treatment 
compared with placebo.  
Montelukast appears to have no performance enhancing effect in non-asthmatic athletes 
(Sandsund et al. 2000; Sue-Chu et al. 2000b). Sue-Chu et al. (2000b) studied 14 highly 
trained, non-asthmatic endurance athletes under ambient temperature of -15°C. They 
showed that administration of 10mg montelukast did not have any beneficial effect on 
the exercise performance. Either no measurable effect on airway function prior to, 
during, or after the exercise protocol was observed. Leukotriene antagonist, in contrast 
to β2-agonists, exhibits their actions by antagonizing the effect of leukotrienes as 
inflammatory mediators (McKenzie and Stewart 2002). Effects should therefore only be 
expected in situations in which there is known production of leukotrienes. An increase in 
leukotriene production has been reported in EIB in asthmatics (Kiwaka et al. 1992; 
Taylor et al. 1992), but has never been reported in healthy, non-asthmatic subjects.   
Mast-cell stabilizers 
Mast-cell stabilizers such as cromolyn or nedocromil sodium have no bronchodilatory 
effect and should not be used to treat acute symptoms. When given about 20 minutes 
before exercise, they prevent asthma symptoms in 70% to 85% of patients with EIA 
(Smith and Labotz 1998).  
Cromolyn sodium is believed to decrease calcium entry into cells, inhibiting mast-cell 
degranulation and subsequent bronchoconstriction (Smith and Labotz 1998). Cromolyn 
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sodium is slightly less effective than β2-agonists in preventing early EIA symptoms. 
However, like nedocromil sodium, cromolyn sodium has anti-inflammatory properties 
and seems to prevent late-phase EIA response. Inhaled mast-cell stabilizers are 
attractive for athletes who exercise repeatedly in a single day. Unlike the β2-agonists,
they cause no side effects and can be taken many times during the day.  
Spooner et al. (2000) concluded in their meta-analysis of 20 randomised trials that 
nedocromil sodium taken before exercise appears to reduce the severity and duration of 
EIB when taken within an hour of an intense, prolonged exercise. The degree of 
protection is most impressive in those patients with more severe EIA. There are no 
published studies assessing the effects of cromolyn or nedocromil sodium on exercise 
performance in elite athletes.
Other 
If the above therapies are unsuccessful, theophylline and ipratropium bromide may be 
considered (Pope and Koenig 2005). Rapid-release theophylline can be taken 1 to 2 
hours before exercise, whereas sustained-release formulations can be taken daily. 
Inhaled anticholinergics need to be taken at least 30 minutes before exercise. A recent 
meta-analysis comparing β2-agonists, chromoglycans, and short-acting anticholinergics 
as prophylaxis for EIB found that although all were superior to placebo, β2-agonists were 
superior to the other agents (Spooner et al. 2003). 
Treatment of allergies 
Nasal allergies may aggravate asthma in people who have EIA (Kobayashi and Mellion 
1991; Briner 1992; Helenius et al. 1996). Nasal allergies by themselves, can also cause 
fatigue, lack of energy, and also reduce exercise performance. It is important to identify 
and treat athletes who have allergies. Oral antihistamines and intranasal steroid sprays 
are the treatments of choice for nasal allergies. Although classic antihistamines can 
cause fatigue, drowsiness, and affect performance, several newer second- and third-
generation H1-receptor antagonists are more selective for peripheral than central H1-
receptors and are non-sedating or at least less sedating than classic antihistamines 
(Montgomery and Deuster 1993; International Consensus Report 1994; MacKnight and 
Mistry 2005).  
The pharmacological treatment of allergies has to comply with antidoping regulations. 
The goal of the therapy is optimum symptom control while minimising the detrimental 
influences on performance from adverse effects. Recently, caffeine, pseudoephedrine 
and phenylpropanolamine were declassified by the WADA. This facilitates the 
pharmacological care of AR in elite athletes and removes the concern for the positive 
test results when these substances are used unintentionally for the management of AR. 
The results of the IOC accredited laboratories show that nearly one-third of the positive 
results for stimulants were for these three substances in 2002 (IOC statistics 2002. 
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Overview on the results reported by the IOC accredited laboratories. 
http://multimedia.olympic.org/pdf/en_report_632.pdf).
Weiner et al. (1998) conducted a meta-analysis of 16 evaluable trials of intranasal 
corticosteroids and oral H1 receptor antagonists in the treatment of AR. Their analysis 
strongly indicates that intranasal corticosteroids are significantly more effective at 
relieving nasal blockage, discharge, and itch, and postnasal drip than are oral 
antihistamines. Intranasal corticosteroids were more effective also at relieving sneezing 
and in reducing total nasal symptoms than were the oral antihistamines, but there was 
significant heterogeneity between the studies. Carrozzi et al. (2001) reported that 
preventive treatment with intranasal corticosteroids, significantly improved symptoms of 
AR, quality-of-life and performance of Australian elite athletes (N = 145). Athletes with 
severe seasonal AR symptoms might benefit from allergen specific immunotherapy, 
which has also prevented an increase in BHR during the pollen season (Walker et al. 
2001).
Non-steroidal anti-inflammatory drugs  
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to suppress inflammation and 
pain after soft-tissue injuries in athletes (Weiler 1992). It has been suggested that the 
use of NSAIDs may be common among elite athletes (Shoor 2002; Thorsson et al. 
1998). However, few estimates are available on the prevalence of NSAID use in elite 
athletes (Corrigan and Kazlauskas 2003; Berglund 2001). No study has compared the 
use of NSAIDs in elite athletes with that in the general population of the same age.  
Prostaglandins are generally considered to be mediators of the inflammatory response 
and as such contribute to pain, swelling, and fever as well as inflammatory processes 
(Almekinders 2002). They are derived from phospholipids from the cell membrane in 
situations in which cell damage occurs. The cell damage can be the result of mechanical 
trauma, chemical irritation, or intrinsic diseases. The liberated phospholipids can be 
converted into arachidonic acid. Through the enzyme cyclooxygenase (COX), 
arachidonic acid can be metabolized into prostaglandins. Prostaglandins can have 
numerous effects, many directly related to the inflammatory response. They contribute 
to vasodilatation, increased capillary permeability, and attraction of inflammatory cells 
and produce pain through direct effects on nerve endings (Belch 1989). The primary 
action of NSAIDs is through inhibition of COX. The decreased production of 
prostaglandins as a result of COX inhibition results in a decrease in the inflammatory 
response. Low doses of NSAIDs may be sufficient to have an analgesic effect whereas 
higher doses are needed to obtain an anti-inflammatory effect as well. 
During the past 40 years, many different NSAIDs have been developed. All NSAIDs 
have the same basic feature of COX inhibition. The chemical structure of NSAIDs is 
quite diverse, although some have a comparable structure and can be categorized on a 
chemical basis.  
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Clinical use of NSAIDs 
NSAIDs are commonly used for musculoskeletal conditions in which prostaglandin-
mediated inflammation produces pain, swelling and other symptoms. These conditions 
can be divided into acute and chronic conditions. Osteoarthritis is the most common 
chronic condition for which NSAIDs are prescribed (Almekinders 2002). Although 
inflammation is not a primary feature of osteoarthritis, NSAIDs can offer pain relief in 
athletes with mild to moderate osteoarthritis who continue their athletic careers. Also 
many other chronic conditions in athletes are often treated with NSAIDs in spite of the 
fact that a clear inflammatory component may not always be present. Tendinitis and 
bursitis are frequently diagnosed as chronic painful conditions in athletes. Although their 
names imply the presence of an inflammatory response, their pathology may be more 
tendinosis meaning degenerated, poorly organized tendon tissue matrix (Khan et al. 
1999; Paavola et al. 2002). 
Acute conditions in which NSAIDs are used include most acute musculoskeletal injuries. 
Fractures, ligament tears or sprains, and muscle-tendon tears or strains are acute 
injuries that clearly evoke an inflammatory response. Pain swelling, redness, and 
impaired function are the classic symptoms of acute inflammation and can be found in 
most fractures, sprains, and strains. The use of NSAIDs can result in a modest inhibition 
of the initial inflammatory response and its symptoms (Almekinders 1999). However, it 
remains controversial whether inhibiting inflammatory response is a uniformly important 
advantage. Pain and disability following the injury are at least in part due to the 
inflammatory response. Decreasing the inflammation decreases the symptoms and may 
allow earlier rehabilitation. On the other hand, the inflammatory response is a 
physiologic way for the body to clear away injured cells and tissue and initiate a 
regenerative, healing response. Without this phagocytic function healing, in particular 
regeneration, may not be able to begin. It is possible that a marked decrease of the 
inflammatory response in an acute athletic injury is not a desired effect.  
Almekinders and Gilbert (1986) raised the question of delayed muscle regeneration as a 
result of anti-inflammatory treatment. Using an experimental animal model, they 
demonstrated that muscle strains continue to weaken in the early post-injury period. 
Histologic examination of the muscle strains revealed delayed inflammatory reaction and 
delayed muscle regeneration in a group treated with piroxicam. Reynolds et al. (1995) 
evaluated the effects of NSAIDs on acute hamstring injuries in a double-blind, placebo-
controlled, randomised trial. Both treatment and placebo groups were treated with the 
same physiotherapy regimen. Reduction of pain and swelling and return to normal 
strength was no better with or without NSAIDs. Surprisingly, in the treatment group with 
severe strains, reduction of pain was better in the placebo group. 
NSAID use in sport and exercise 
Muscle activation is inhibited in the presence of pain (Herbison 1979). Physiologic 
adaptation mechanism usually decreases use of the painful structure and thus protects it 
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from further injury. Athletes and also their coaches often want to override this pain 
inhibition in order to maintain athletes exercise performance.  
The use of NSAIDs has become widely accepted as routine treatment of soft-tissue 
injuries (Buckwalter 1995). Few physicians or patients question the effectiveness of the 
commonly used NSAIDs or carefully consider their potential adverse effects on injured 
area or their potential systemic toxicity. Many athletes with minor injuries do not take 
enough time off training or competition to allow proper healing. Instead of temporary 
immobilization and local cryotherapy, they begin to treat their problems with NSAIDs and 
continue exercising.  
COX-2 activity is important during the early stages of muscle regeneration (Bondeson et 
al. 2004). Inflammation has a role in initiating and promoting the repair of vascularizied 
tissues (Buckwalter 1995). In addition, because pain that is due to inflammation may 
limit activity that can cause additional injury, it is reasonable to question whether 
suppression of pain and inflammation adversely affects healing. 
All NSAIDs, due to their inhibition of prostaglandin synthesis, can have adverse effects 
(Simon 1996; Hawkey et al. 2003; Verrico et al. 2003). NSAID-induced gastrointestinal 
adverse effects are a major problem. One might think that the adverse reactions caused 
by NSAIDs are not a health risk for otherwise healthy athletes who use them to treat 
temporary pain and inflammation from an injury. However, changes in renal function 
(Baker et al. 2005) and even renal damage has been reported in athletes taking NSAIDs 
during exercise (Irving et al. 1990; Vitting et al. 1986; Walker 1994). This may be even 
life-threatening in excessive heat (Griffiths 1992). Long-term use of NSAIDs (especially 
indomethacin) has also been associated with accelerated progression of hip and knee 
osteoarthritis (Rashad et al. 1989; Huskisson et al. 1995; Reijman et al. 2005). 
The selective cyclooxygenase-2 (COX-2) inhibitors have been suggested to be as 
effective as nonselective NSAIDs in reducing inflammation and pain while causing fewer 
adverse effects such as peptic ulcers (Seibert et al. 1997). However, COX-2 inhibitors 
are not without problems of their own (Verrico et al. 2003). Questions have been raised 
about their cardiovascular side effects (Mukherjee et al. 2001; Ray et al. 2002). Recently, 
rofecoxib and valdecoxib have been withdrawn from the market. In addition, several 
studies have showed that cyclooxygenase-1 (COX-1) also plays a role in the 
inflammation model (Crofford et al. 1994; Gilroy et al. 1998; Gretzer et al. 1998; Wallace 
et al. 1999; Gierer et al. 2005). Gretzer et al. (1998) reported that in chronic bursitis most 
prostaglandins are not synthesized via the COX-2 pathway. Selective COX-2 inhibitors 
inhibited prostaglandin formation in human bursal tissue only at high concentrations that 
also inhibited COX-1, while concentrations selective for COX-2 had no significant 
inhibitory activity on bursal tissue. Selective inhibition of COX-2 may not be sufficient to 
produce the full range of anti-inflammatory activities associated with standard NSAIDs. 
Thus, the classical dual inhibitors of COX-1 and COX-2 may be more appropriate for 
treating chronic inflammation (Gilroy et al. 1998).  
NSAIDs have been used for the prevention of heterotopic ossification (Banovac et al. 
2004). Increasing evidence suggests that their regular use may also interfere with 
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fracture healing (Altman et al. 1995; Burd et al. 2001; Endo et al. 2002). These agents 
may be especially harmful when used in connection with stress fractures known to heal 
slowly, such as navicular or Jones' fractures. COX-2-dependent prostaglandin synthesis 
is required during muscle regeneration (Bondesen et al. 2004). Administration of COX-2 
inhibitors soon after muscle injury, while providing the desired analgesic effects, may 
adversely affect muscle regeneration.  In animal models that COX-2 inhibitors have 
impaired ligament healing (Elder et al. 2001).  
Prostaglandins have also been shown to regulate protein metabolism, and NSAIDs have 
been shown to blunt protein metabolism in animal skeletal muscle (Rodemann and 
Goldberg 1982; Palmer 1990). Prostaglandin (PG)F2α is a product of the COX enzyme 
and has been shown to stimulate skeletal muscle protein synthesis (Rodemann and 
Goldberg 1982; Palmer 1990). Trappe et al. (2001) observed that (PG)F2α is increased 
in human skeletal muscle after eccentric resistance exercise. Ibuprofen and paracetamol 
attenuated PG response when consumed at maximal over-the-counter (OTC) doses 
(max. OTC dose for ibuprofen is 1200 mg per day). The same authors (2002) reported 
that the increased rate of muscle protein synthesis normally seen 24 h after high-
intensity eccentric resistance exercise was attenuated by consumption of ibuprofen and 
paracetamol at OTC levels. Thus, long-term use of NSAIDs may inhibit the normal 
hypertrophic response to resistance training. 
Treating DOMS with NSAIDs  
It has been proposed that the inflammatory process and the accumulation of muscle 
oedema following tissue injury can contribute significantly to the development of DOMS. 
As a result, both prophylactic (prior exercise) and therapeutic (post-exercise) use of 
NSAIDs for the treatment of DOMS has been observed in athletes (Almekinders 2002). 
NSAIDs prevent the production of endoperoxides and prostaglandins. Reduced muscle 
edema and intramuscular pressure as a result of reduced inflammatory response could 
contribute to reduce pain and muscle soreness. Thus NSAIDs seem a logical choice to 
avoid or treat DOMS. 
The studies on the use of NSAIDs in DOMS have yielded conflicting results. Some have 
shown a mild improvement of the symptoms and/or the chemical parameters of DOMS 
(Francis and Hoobler 1987; Hasson et al. 1992 and 1993; Dudley et al. 1997; Lecomte 
1998;). However, majority studies have not found significant differences over placebo 
treatment (Kuipers 1985; Donnely 1990; Bourgeois 1999; Pizza 1999; Semark et al. 
1999; Barlas et al. 2000). It can be concluded that NSAIDs have, at best, only a small 
beneficial effect on DOMS. Almekinders (2002) has also discussed that in elite athletes 
DOMS is not considered to be a major problem. The soreness as a consequence of 
eccentric exercise has a distinct tendency to decrease or even disappear after repeated 
bouts of eccentric exercise. Many elite athletes train year-round and it keeps them 
accustomed to eccentric exercise. Additionally regular prophylactic use of NSAIDs may 
inhibit the normal hypertrophic response to resistance training (Trappe et al. 2002). 
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Topical  preparations of NSAIDs 
Topical NSAID preparations have the potential to deliver the drugs directly to the injured 
tissues. This transdermal delivery eliminates gastrointestinal metabolism of the drugs 
and reduces their effects on the liver and kidneys. Few investigators have studied 
transdermal delivery of NSAIDs, but the available evidence shows that these drugs can 
penetrate three to four millimeters when applied to the skin (Singh and Roberts 1994; 
van den Ouweland et al. 1989). From this depth, they can enter the cutaneous vascular 
system and then be distributed to deeper tissues as well as systemically (van den 
Ouweland et al. 1989). Several clinical studies of the topical application of NSAIDs, 
including diclofenac, ibuprofen, naproxen, and piroxicam, for the treatment of acute soft-
tissue injuries, including ankle sprains and muscle strains, have indicated that they 
decrease pain, tenderness, swelling and stiffness (Kroll et al.1989; Bouchier-Hayes et 
al. 1990; Jenoure et al. 1993; Butron et al. 1994; Campbell and Dunn 1994).  
NSAIDs or analgesics without anti-inflammatory effects? 
The ideal treatment for muscle injuries remains uncertain. NSAIDs may decrease the 
inflammatory response and thereby the pain and swelling (Almekinders 1999). It has 
also been observed that inflammatory response is a necessary phase during soft tissue 
healing (Järvinen et al. 1992) and inhibition of this phase may result in poor healing as 
has been shown with corticosteroids (Beiner and Jolk 1999). The analgesic effect of 
NSAIDs may, however, be a central nervous system effect (McCormack and Brune 
1991) and not necessarily related to their anti-inflammatory effects. Therefore, 
analgesics without anti-inflammatory effects may have similar effects as NSAIDs in soft 
tissue injuries. 
Rahusen et al. (2004) observed in a controlled animal study (N=96) that selective COX-
2 inhibitor rofecoxib and paracetamol had similar effects when an experimental, acute 
muscle contusion model was used. Decrease in wet weights was observed similarly in 
all treatment groups at day 2 compared to the placebo-treated group. This may suggest 
an anti-inflammatory effect because the wet weight should be a reflection of oedema 
within the muscle. However, also the paracetamol-treated animals had similar wet 
weights, which suggest that the wet weights were decreased as a result of continued 
use of the muscle rather than anti-inflammatory action. Continued normal use of the 
extremity will promote circulation, which is likely to minimize any post-injury swelling. 
The increased use may be related to the analgesia. It is possible that non-selective 
NSAIDs have different effects in this injury model. However, the authors concluded that 
without clear evidence of their effectiveness, the use of NSAIDs in muscle injury should 
be critically evaluated, and costs and side effects should be weighed against evidence 
of efficacy. Safer and less costly medications like paracetamol may have equal effects. 
It should be noted that the animal studies have limited translation to the clinical setting, 
particularly because of significant limitations relating to drug use and dosage in these 
studies. Currently, there is no randomised, controlled trial evidence of the tissue-level 
effects of selective COX-2 inhibitors on acute musculoskeletal injuries. 
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THE EFFECTS OF EXERCISE ON DRUG THERAPY 
Athletes exercise in order to improve their sport performance. Exercise alters number 
physiological factors that may have an effect on the pharmacokinetics of some drugs. 
Pharmacokinetics describes the relationship between the absorption, distribution, 
metabolism, and excretion of medicine and its duration of action. Exercise can have a 
significant effect on one or more of these areas.  
Exercise and physiological changes 
Blood flow alteration is one of the most influential factors that may change drug kinetics 
(Lenz et al. 2004). Generally, blood flow to a specific tissue is related to metabolic 
activity of that tissue. Exercise redistributes blood flow away from the gastrointestinal 
tract towards the active muscles and lungs and results in a reduction in splanchnic –
hepatic blood flow (Khazaeinia et al 2000). Reduction in splanchnic blood flow is related 
to the relative intensity of the exercise. Splanchnic blood flow is reduced by 
approximately 50% at an exercise intensity of 70% of the maximum oxygen uptake. 
Blood flow to the gut is reduced up to 80% during intensive exercise. At rest, in humans, 
skeletal muscle receives between 15% and 20% of the cardiac output, while during 
maximal exercise, this percentage reaches 80% to 90% (Frank et al. 1990, McArdle et 
al. 2001). With maximum level of exercise cardiac output is approximately 25.0L/min, 
which is a five-fold increase compared with rest. The higher the intensity of the activity, 
the greater the blood flow to the working muscles.  
Drug absorption during exercise 
Drug absorption can occur at a number of different sites including the gastrointestinal 
tract, subcutaneous, intramuscular and transdermal tissues, and in the lungs through 
inhalation. Exercise can potentially affect absorption at each of these sites. When the 
exercise intensity reaches 70% of the maximum oxygen uptake, gastric emptying slows 
and absorption of drugs may be delayed. Cordain et al. (1986) demonstrated that bowel 
transit time decreases as a result of a 6-week anaerobic training. Decreases in bowel 
transit time during exercise may not allow adequate time for absorption. 
Because blood flow increases to working muscles and the skin, drugs that are 
administered subcutaneously, intramuscularly or transdermally, may have altered 
pharmacokinetics if given at or near the time of exercise. The rate of absorption of 
insulin has been demonstrated to increase significantly after subcutaneous injections in 
working muscles, but not in non-working muscles. Koivisto and Felig (1978) showed that 
exercise can significantly affect blood glucose levels if insulin is administered prior to 
exercising. The rate of insulin disappearance from the injection site (leg) during the first 
10 minutes of exercise was 135% higher than at rest.  Over the entire 1-hour exercise 
period, the amount of insulin absorbed was 50% more than at rest. Blood glucose 
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remained suppressed for 2-5 hours after exercise. The proper administration of insulin is 
critical to maintain an adequate blood sugar level. 
Exercising with a transdermal patch has been shown to increase plasma drug 
concentrations (Klemsdal et al. 1992 and 1995). This is most likely due to the increased 
blood flow to the skin, increased skin temperature and increased hydration.  
Increased pulmonary blood flow may increase the absorption of inhaled medicines. 
Schmekel et al. (1992) demonstrated that inhalation of terbutaline just prior to a 30-min 
exercise challenge on a bicycle ergometer lowered time to maximum plasma 
concentration (tmax from 53±8 to 26±7 min) and increased peak plasma concentrations 
(Cmax from 11.4±3.7 to 17.3±7.1 nmol/L). Higher plasma levels may enhance the 
propensity to develop systemic side effects, such as tachycardia and disturbances of the 
electrolyte and carbohydrate metabolism. Therefore, it is recommended to increase the 
frequency of drug administration rather than increase the dose in order to prevent or 
ameliorate the development of EIA. Also smoking increases the rate of terbutaline 
absorption and the peak plasma concentration achieved (Schmekel et al. 1991). This 
may be relevant to therapeutic effect of terbutaline, by giving a faster onset of action and 
a shorter duration of the therapeutic effect in smokers than in non-smokers. 
Drug distribution during exercise 
Drug distribution is dependent on several factors. The delivery of the drug to the tissues, 
the passage of the drug through tissue membranes and the binding of the drug to 
plasma proteins and other tissue components are all key steps in drug distribution (Lenz 
et al. 2004). Exercise has been shown to change drug binding to plasma proteins and 
tissues. Plasma protein concentrations increase during exercise due to loss of water 
from plasma into the tissues (van Baak 1990). This may influence drug binding to 
plasma proteins and tissues. It has also been theorised that alterations in drug 
distribution may occur due to the redistribution of blood to active muscles causing an 
inability of the drug to reach its intended site of action. The volume of distribution of 
several drugs such as theophylline, propranolol and indomethacin has been shown to 
change as a result of exercise (Henry et al.1981).  
Drug metabolism during exercise 
Drug metabolism takes place in several organs. The liver has the greatest metabolic 
capacity and is principally responsible for drug metabolism (Lenz et al. 2004). Several 
factors, such as blood flow and metabolic enzyme activity, can influence metabolic 
process. Depending on its physical and chemical properties, each drug is taken up and 
extracted by the liver to different degrees. Knowing the affinity of drugs for extraction by 
the liver can be important information when trying to predict various influences on drug 
metabolism.
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Hepatic extraction rate can vary from low to high extraction. Drugs, such as 
paracetamol, doxycycline, insulin and theophylline, have a low hepatic extraction 
(<20%). Metabolism of these drugs is dependent upon metabolic enzyme activity and 
the unbound fraction of the drug present in plasma. Blood flow changes in the liver 
during the exercise have not been shown to affect the metabolism of low extraction 
drugs. However, metabolism of these drugs may be affected by physical conditioning. It 
has been shown that improved physical fitness levels stimulate liver oxidative 
metabolism. Villa et al. (1999) observed that phenazone (antipyrine), a very low hepatic 
extraction drug, has a significantly higher clearance (0.44 and 0.35 mL/min/kg) and 
lower half-life (11.6 and 15.2h) in trained versus untrained individuals, respectively.  
Drugs with a high hepatic extraction have a metabolism that is dependent on blood flow 
through the liver and tend to be less available to the systemic circulation. The shift in 
blood flow away from the liver during exercise has been shown to alter the clearance of 
high extraction drugs. The clearance of these drugs due to exercise only occurs during 
the time of blood flow alteration. 
Drug excretion during exercise 
Excretion is defined as a process of removing a drug from circulation. This process can 
take place through the urine, bile, sweat, expired air, breast milk, or seminal fluid (Lenz 
et al. 2004). The primary excretion routes for most drugs are through the urine and bile. 
Renal excretion is the net effect of glomerular filtration, tubular secretion and tubular 
reabsorption. The rate of glomerular filtration is dependent on the amount of blood flow 
into the kidneys. Exercise decreases renal blood flow by 50-60% and glomerural 
filtration rates (GFR) by 30-40% (Suzuki et al. 1996, Baker et al. 2005). The greater the 
exercise intensity the less renal blood flow and therefore the lower the glomerular 
filtration rate. Suzuki et al. (1996) reported that exhaustive exercise reduced renal blood 
flow by 53% compared with pre-exercise renal blood flow. During the post-exercise 
recovery period, renal blood flow returned to nearly 80% of pre-exercise value at 30 and 
60 minutes. Reductions in creatinine and urine volume also accompanied renal blood 
flow changes immediately following and at 30 minutes post-exercise. Drugs most likely 
affected by exercise are those that are primarily excreted unchanged in the urine or 
whose elimination is dependent on renal function.  
Ylitalo et al. (1977) showed that serum levels of doxycycline and tetracycline and the 
area under the serum concentration-time curve were elevated significantly more during 
exercise than during rest. The excretion of doxycycline and tetracycline was lower 
during exercise than during rest. The reduction in drug excretion during exercise may be 
partly explained by the diminished urine production rate, but was also contributed by the 
reduction in urine pH. In addition to the delay in drug elimination, the absorption of the 
drug appeared to be more rapid during exercise than during rest, which also contributed 
to elevated concentration levels.  
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NSAIDs and the effects on pharmacokinetics 
Ryan et al. (1996) observed that when 1.3g of aspirin was ingested the night before and 
immediately prior to moderate (60 min at 68% VO2max) treadmill running both the 
intestinal and gastroduodenal permeability were increased. Marked elevation of GI 
permeation of lactulose was observed after this acute ingestion of aspirin. Enhanced 
intestinal permeability may contribute to the pathogenesis of diarrhea or abdominal 
cramps in some runners, presumably via enhancing mucosal exposure to luminal 
antigens with the consequent of generation of a local inflammatory response (Oktedalen 
1992). 
Farquhar et al. (1999) demonstrated that ibuprofen, under stressed conditions of salt 
restriction, dehydration, and heat, produced a significantly greater decrease in GFR after 
45 min of exercise at 65% VO2max, when compared with placebo or paracetamol. Baker 
et al. (2005) reported that indomethacin and celecoxib induced significant inhibition of 
free water clearance at the end of exercise period (30 min treadmill running at 80% 
VO2max) compared with placebo.  Free water clearance remained lower during 2-hour 
recovery in both treatment groups than in placebo. The potential clinical risk of impaired 
free water clearance after exercise is the development of hyponatremia and more rarely 
acute cerebral edema. There have been a number of observational studies reporting the 
occurrence of hyponatremia in athletes participating in endurance events (Ayus et al. 
2000; Davis et al. 2001; Hsieh et al. 2002; Noakes 2002). 
DOPING
The World Anti-Doping Code declares a drug illegal if it is a performance enhancing, if it 
is a health risk, or if it violates the spirit of sport (WADA 2003). According to Yesalis et 
al. (2001) our concerns over use of banned substances in sport are generally based in 
one or more of the following moral and ethical issues:   
1.) the athlete may suffer physical or psychophysical harms as a result of drug use, 2.) 
the use of drugs by one athlete may coerce other athletes to use drugs to maintain 
parity, 3.) the use of drugs in sport is unnatural in that any resulting success is due to 
external factors, and 4.) the athlete who uses drugs has an unfair advantage over 
athletes who do not use them.
Given these concerns, it is important to be able to accurately assess the magnitude of 
drug use in sport. If we underestimate drug use, it is very likely that these concerns will, 
at least in part, be realized. If we overestimate drug use, we could injure the reputations 
of individuals, teams, or even nations. 
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STUDY METHODS FOR ASSESSING MEDICINE USE AND 
PREVALENCE OF DOPING 
Pharmacoepidemiology in general population 
Pharmacoepidemiology is defined as a study that provides information of the medicine 
use, changes of consumption, and effects of healthcare products (Thomson and Poulton 
2002; Epstein 2005). Use of medicines may reflect morbidity and its changes, health 
behaviour and appropriateness of medication use in general (Thomson and Poulton 
2002; Linden 2005). Pharmacoepidemiology is the scientific backbone of therapeutic 
risk management –the process of assessing a product’s benefits and risks, and 
developing, implementing, and evaluating strategies to enhance the overall balance of 
benefits and risks (Epstein 2005). A new topic in the field of pharmacoepidemiology 
concerns adverse event reporting in pharmacoepidemiologic studies. 
Medication use and its changes in outpatient populations can be estimated by the 
statistics on the wholesales of medicines in monetary units, in number of packages or 
tablets or other medicine units, or in the defined daily doses (DDD; Internet page for 
WHO International Working Group for Drug Statistics Methodology, 
http://www.whocc.no/atcddd; Linden 2005). The number of prescriptions in pharmacy, 
reimbursements or other health care register can also be used to assess medicine use. 
More detailed information on the medicine consumption of individuals can be reached by 
surveys or medicine use diaries (Thomson and Poulton 2002; Holstein et al. 2003).  
Accurate medication recall is important to the validity of pharmacoepidemiologic studies 
(Kimmel et al. 2003). One strategy to enhance participants’ recall of past medication use 
is to read a list of names of the medication of interest and to provide participants with 
photographs of the actual medicines (West et al. 2000). Kimmel et al. (2003) reported 
that the use of this type of memory aid reduced recall bias somewhat in a case-control 
study that relied on medication recall. Personal interviews with the check of the medicine 
packages or prescriptions may provide more reliable information than independently 
completed questionnaires (Aromaa et al. 1986). In the questionnaires, open questions 
on the medicine use or recalling brand names may result in lower prevalence of 
medicine use than use of common indications (Klungel et al. 2000). Compared to cross-
sectional studies, longitudinal studies may provide more information, for example, on the 
changes in medicine consumption, association between the use of medicines and health 
care services or between the prescribed and nonprescribed medicines (Sinclair et al. 
2001). 
Difficulties in estimating the prevalence of drug use among athletes 
Until the mid-1970s, all that was known regarding the incidence of performance-
enhancing drug use in sport was based on anecdotes, testimonials, and rumors reported 
by journalists and others. The writings and testimonials of former athletes and others in 
or around sport generally have confirmed that doping in sport is a serious problem. 
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Much of the writing on the use of drugs in sport is still focused on anecdotal evidence. 
There is very little rigorous, objective evidence because the athletes are doing 
something that is taboo, illegal, and sometimes highly dangerous (Savulescu et al. 
2004). Although investigative journalism still is an indicator of the drug use in sport, 
other sources of information also are available. These include government records and 
investigations as well as the results of systematic surveys and drug testing associated 
with athletic competition (Yesalis et al.  2001). 
Investigative journalism 
Investigative methods assessing the incidence of performance-enhancing drug use in 
sport are often less expensive and time-consuming than the other methods. However, 
they have number of methodological limitations. Journalists use primarily personal 
observations, accounts, or opinions of self-selected informants. Individuals who use or 
have used drugs and serve as informants may project their behaviour onto others in an 
attempt to rationalize their drug use –as they say, “Everybody does it.” Consequently, an 
overestimate of the level of drug use may result. Athletes and all the others involved in 
competition may also either refuse to co-operate with journalists or deny drug use to 
protect themselves, team mates, their school, or the reputation of their sport. 
Testimonials on drug use in sport are generally only given by former athletes, because 
current athletes fear possible retribution from coaches, team mates, or sport federation 
officials. Even former athletes may be reticent to discuss drug use because it could 
result in the loss of paid speaking engagements, endorsements, and induction into halls 
of fame.  
Another potential problem within investigative journalism is the scope of the investigation 
and its effect on the generalizability of the findings. Often reports focus on a few 
athletes, teams, or sports. Even if the findings are valid, they most likely cannot be 
legitimately generalized beyond the scope on investigation. 
Government investigation 
During government hearings, current and former athletes, and some coaches and sport 
federation officials, with few exceptions, have supported the notion that there is a 
significant doping problem. From a methodological perspective, volunteered opinions 
and observations of a relatively small sample of individuals, selected in a non-random 
manner, have been used to estimate the extent of doping in a relatively small number of 
sports at various levels of competition (Yesalis et al.  2001). 
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Drug testing  
According to the International Olympic Committee’s and WADA’s official statistics, 
annually 1-2% of all the doping tests are positive. According to most of the conclusions 
of investigations conducted by journalists and the governments, the real prevalence of 
use performance-enhancing substances is significantly higher than this. Also the 
previous surveys have shown that the real prevalence of doping among athletes is 
considerably higher than the drug testing reveals (Scarpino et al. 1990; Yesalis et al. 
1990; Yesalis and Bahrke 1995; Laure and Reinsberger 1995; Laure 1997; Bents et al. 
2004). Drug testing probably underestimates the real level of performance-enhancing 
drug use because testing can be circumvented by the user. According to Waddington 
(2000) the incidence of positive tests is a poor –some would argue so poor as virtually 
useless- index of the extent of drug use in elite sport. In the case of testing only at 
competitive events, athletes usually can determine when to discontinue use of drugs 
prior to testing in order to allow metabolites of the drugs to clear the body. There are 
also several strategies for athletes to successfully circumvent unannounced, out-of-
competition testing. Athletes can titrate their dose by using transdermal patches or skin 
creams containing testosterone when they use private laboratories for self-testing. Lack 
of the effective tests for detection certain performance-enhancing drugs such as human 
growth hormone and insulin-like growth factor is another factor allowing drug-using 
athletes to escape detection.  
Surveys 
Survey research is dependent on self-reported data about the attitudes, motivations, and 
behaviours known only to the respondent. Research work based on questionnaires 
covering a prohibited practice has limits: answers may be intentionally false as the 
subjects questioned may not wish to reveal that they or their team mates use drugs, 
even if anonymity and confidentiality are guaranteed by the investigators. Thus, the 
extent to which athlete respondents honestly report their drug use is unknown.
Moreover, some substances such as cannabis, cocaine, and narcotic analgesics, 
although banned or controlled, are not considered as doping by some athletes (Laure 
and Reinsberger 1995). In order to answer questionnaire, the athlete must also know 
the name or pharmacological category of the drug(s) used. 
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AIMS OF THE STUDY 
General aim of the present study was to investigate the use of physician-prescribed 
medicines and the factors associated to their use in Finnish elite athletes. The 
prevalence of use of medicines was compared with results from a representative sample 
of the same-age general population. The athletes’ attitudes and beliefs towards use of 
banned substances and methods in sport were also clarified. All the results were 
compared between different type of sports: The specific questions were as follows: 
1. What is the frequency of medication use (antiasthmatic, antiallergic, NSAIDs, oral 
antibiotics) and factors associated with those? 
2. What is the difference of use of medication between different sport activities? 
3. What is the frequency of adverse effects related to the use of physician-
prescribed NSAIDs? 
4. What are the attitudes and beliefs of elite athletes towards use and effects of 
banned substances in different sports? 
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SUBJECTS AND METHODS 
Study design for athletes 
A cross-sectional survey was carried out during May-October in 2002. In Finland, 
National Olympic Committee provides financial support for 1) athletes with Olympic 
Medal possibilities (N = 54), 2) athletes who probably will participate in the next Olympic 
Games (N = 109), and 3) young athletes who probably will participate in the Olympic 
Games in the future (N = 132). National Olympic Committee supports financially also 
Olympic team sport events and some non-Olympic events such as orienteering and ski-
orienteering (N = 199). All these athletes (N = 494) comprised the target population for 
this study. They were asked to complete the questionnaire on their national team camps 
in 2002 and to those absent, the questionnaire was sent by mail. Of the 494 athletes, 
446 (90.3%) completed a semi-structured questionnaire after accepting written informed 
consent. The athletes had a possibility to consultate the author when filling in the 
questionnaire. The athletes were divided into four groups according to their type of sport: 
1) speed and power sport athletes, 2) endurance athletes, 3) athletes in motor skills 
demanding events, 4) team sport athletes (Table 4). The characteristics of the study 
groups are given in the Table 5.  
TABLE 4. Participating athletes by type of sport. 
Winter 
events 
N = 180 Response
rate
Summer  
events 
N = 266 Response rate 
Speed and 
 power 
Freestyle 
Speed skating 
Alpine events 
93.1% 
 (27 of 29) 
Speed and 
power 
Track and field 
  (Sprinters, hurdlers,   
   jumpers, throwers, 
   decathletes) 
Weight lifting 
Karate 
Boxing 
Wrestling 
Taekwondo 
Judo
87.8% 
 (86 of 98) 
   Endurance Cross-country skiing 
Nordic combined 
Biathlon
Orienteering on skis 
96.0%
(48 of 50) 
   Endurance Swimming 
Track and field (800m+) 
Squash 
Cycling 
Badminton 
Aerobic 
Orienteering 
Rowing 
Canoeing
87.0% 
 (60 of 69) 
   Motor skills  
   demanding          
Figure skating 
Ski jumping 
Snow boarding 
Curling
79.3%   
(23 of 29) 
   Motor skills  
  demanding            
Bowling 
Diving 
Shooting 
Archery 
Sailing 
Gymnastics 
Horse riding 
Dancing
87.0%  
(50 of 60) 
   Team sports Ice hockey (women) 
Ice hockey (women U-22)1
Ice hockey (men U-20) 
97.6%  
(82 of 84) 
   Team sports Basketball (women) 
Soccer (women) 
Soccer (Olympic team) 
Volleyball (men) 
Handball
93.3%  
(70 of 75) 
1U-22=Under 22 year-old 
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Control subjects 
The reference group comprised all those aged 18-29 years (N = 1894) from the Finnish 
national health survey Health 2000, coordinated by the National Public Health Institute 
(Koskinen et al. 2005). A nationally representative two-stage cluster sample was drawn, 
which consisted of 10 000 individuals and 80 regions (municipalities, or groups of 
municipalities with joint primary care). The sample included inhabitants of all the 15 
largest cities and towns. The sub-study of younger adults aged 18 to 29 included a 
computer-aided health interview - carried out in 2001. The final sample of those aged 18 
to 29 numbered 1876, of whom 1504 (80.2%) participated in the health interview. Data 
were collected, stored, analysed, and reported anonymously according to the law on 
data protection in Finland.  
TABLE 5. Characteristics of the study groups and the controls 
 All 
athletes 
N = 446 
Speed and 
power 
Events
N = 113 
Endurance 
Events
N = 108 
Motor skills 
demanding 
events 
N = 73 
Team sport 
events 
N = 152 
Controls 
N = 1504 
Sex       
   Male 261 82 62 45 72 766 
   Female 185 31 46 28 80 738 
Mean (SD) age (years) 23.0 (4.5) 23.8 (4.1) 23.6 (4.0) 23.6 (6.5) 21.6 (3.6) 23.4 (3.5) 
Mean (SD) duration of 
active sport career (years)
11.7 (4.3) 12.2 (3.7) 12.4 (4.6) 11.9 (5.0) 10.8 (4.1) __ 
Mean (SD) training 
amount (hours per week) 
15.4 (6.1) 15.5 (4.6) 17.3 (5.9) 15.1 (7.4) 14.1 (6.3) __ 
Education       
   High school 67.5 (301) 59.3 (67) 78.7 (85) 64.4 (47) 67.1 (102) 42.6 (641) 
   Comprehensive school/ 
   Vocational school 
32.5 (145) 40.7 (46) 21.3 (23)  35.6 (26) 32.9 (50) 57.4 (863) 
Smoking status       
   Never smoker 77.6 (346) 80.5 (91) 91.7 (99) 74.0 (54) 67.1 (102) 44.1 (663) 
   Ex-smoker 11.0 (49) 12.4 (14) 5.6 (6) 6.8 (5) 15.8 (24) 17.6 (265) 
   Current smoker 11.4 (51) 7.1 (8) 2.8 (3) 19.2 (14) 17.1 (26) 38.3 (576) 
Original sample size 494 127 119 89 159 1 876 
Response rate (%) 90.3 89.0 90.8 82.0 95.6 80.2 
Questionnaire 
A semi-structured questionnaire used in the athlete study was based on the 
questionnaire used in the Health 2000 survey. The questionnaire was piloted with 
national level ice-hockey players and track and field athletes (N=30) who were not 
included in the final study. All the subjects were asked the following questions: (1) “Have 
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you used any medication prescribed by the physician during previous 12 months of the 
study (yes/no)?” (2) “Do you have any current medication in use (yes/no)?”  If the 
subjects answered positively they were asked to name all the physician-prescribed 
preparations they had in use. They were further asked whether they had used the named 
preparations during previous seven days, and whether the preparations were in regular 
or occasional use or used only when needed.
In addition to the abovementioned questions, athletes were asked to name all the 
medicines they had used during previous 12 months of the study. They were further 
asked about frequency and dosage of NSAIDs they had used and whether they had 
noticed any adverse effects related to the use of NSAIDs. Used medications were 
categorized using Anatomical Therapeutic Chemical (ATC) classification (Internet page 
for WHO International Working Group for Drug Statistics Methodology, 
http://www.whocc.no/atcddd). Oral contraceptives were not included in physician-
prescribed medications. 
Questions concerning asthma and allergies 
Subjects were asked the following questions: “Do you have asthma diagnosed by a 
physician?” If the subject answered positively he was considered to have asthma.  All the 
subjects were asked “Do you currently use any antiasthmatic medication?” Athletes were 
also asked about the prevalence of exercise-induced bronchial symptoms “How often do 
you have cough, shortness of breath or wheeze in connection to exercise (each 
symptom asked separately): (a) daily, (b) weekly, (c) monthly, (d) in connection to 
respiratory infections, (e) never?” 
The subjects were asked whether they had a disturbing allergy that had been diagnosed 
by a physician. When the subject responded affirmatively to the question the subject was 
further asked whether the condition was allergic rhinitis, allergic conjunctivitis, atopic 
eczema or other. The subjects were also asked whether they had any current medication 
for their condition.  
Antiasthmatic and allergy medication were classified as inhaled ? β2-agonists, inhaled 
corticosteroids, cromones (sodium cromoglycate and nedocromil), leukotriene 
antagonists and oral antihistamines. Inhaled β2-agonists were further classified as short-
acting (salbutamol and terbutaline) and long-acting (salmeterol and formoterol) ? β2-
agonists. 
In the results section, sympathomimetics include products containing 
phenylpropanolamine or pseudoephedrine. Antiallergic nasal sprays without 
corticosteroids include products containing disodium cromoglycate or levocabastine. 
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Statistical methods 
The odds ratios (OR) for studied variables and their 95% confidence intervals (95% CI) 
for athlete subgroups compared with controls were analyzed using a logistic regression 
model (Statistical package for the social sciences; SPSS 10.0 software). Age, sex, 
smoking and type of sport were included as independent covariates in the analysis.  
In study II the sample-size requirement was calculated using a study power of 80%, a 
type-I error α ?of 0.05, and an estimated occurrence of 10% and 5% for use of 
antiasthmatic medication in the athlete and control group respectively. A total of 434 
study subjects in both groups were required to identify a 5% difference in medication 
rates between these groups. 
In study III the sample-size requirement was calculated using a study power of 80%, a 
Type I error α of 0.05, and an estimated prevalence of 25% and 15% for use of 
antiallergic medication in the athlete and control group, respectively. A total of 249 study 
subjects in both groups were required to identify a 10% difference in medication rates 
between these groups. 
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RESULTS 
Use of physician-prescribed medication (Study I) 
Any physician-prescribed medication was used by 74.4% (332 of 446) of the athletes and 
56.4% (848 of 1503) of the controls during the previous 12 months of the study  (P < 
0.001). After adjusting for age and sex, the OR (95% CI) for use of any prescribed 
medication was 2.30 (1.81-2.92) in the athletes compared with the control population. In 
the athlete subgroups, the adjusted OR (95% CI) for any prescribed medication was 3.12 
(1.93-5.04) for speed and power athletes, 3.17 (1.95-5.17) for endurance athletes, 1.14 
(0.71-1.84) for athletes in motor skill-demanding events, and 2.24 (1.54-3.27) for team 
sport athletes compared with the controls. 
A total of 34.5% (154 of 446) of the athletes had used some physician-prescribed 
medication during the previous seven days compared with 24.9% (374 of 1503) of the 
controls. The most frequently reported physician-prescribed medications in the athletes 
were antiallergic medicines (12.6% of the respondents), NSAIDs (8.1%), antiasthmatic 
medicines (7.0%), and oral antibiotics (2.7%). Medication use among the controls 
followed analogous patterns, although the prevalences were lower. Data for the athlete 
subgroups are shown in Table 6. The age- and sex-adjusted ORs (95% CI) for use of 
any prescribed medication during the previous seven days in the athletes compared with 
the controls are shown in Table 7.  
NSAIDs 
A total of 49.1% (219 of 446) of the athletes had used physician-prescribed NSAIDs 
during the previous 12 months. No difference was observed in the prevalence of use 
between female and male athletes [48.6% (90 of 185) of the females and 49.4% (129 of 
261) of the males]. The athletes in speed and power events reported use of physician-
prescribed NSAIDs most frequently [59.3% (67 of 113)] and athletes in motor 
skill-demanding events least frequently [37.0% (27 of 73)]. A total of 2.0% (9 of 446) of 
the athletes reported using physician-prescribed NSAIDs daily or almost daily, 4.9% (22 
of 446) weekly and 10.8% (48 of 446) at least once per month.  
Physician-prescribed NSAIDs were used during the previous seven days by 8.1% (36 
of 446) and 2.7% (40 of 1503) of the athletes and controls, respectively. The age- and 
sex-adjusted OR (95% CI) for physician-prescribed NSAID use during the previous 
seven days was 3.63 (2.25-5.84) in the athletes as compared with the controls. Of the 
athlete groups, speed and power athletes had the highest OR (OR 9.5; 95% CI 5.18-
17.4; Table 7). Three athletes reported concomitant use of more than one NSAID 
(active ingredient) during the previous seven days. 
The most commonly used physician-prescribed NSAIDs among athletes during the 
previous 12 months were propionic acid derivatives (ibuprofen, naxopren, ketoprofen)
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reported by 28.0% (125 of 446) of the athletes and acetic acid derivatives 
(indomethacin, diclofenac) reported by 13.5% (60 of 446) of the athletes. Use of coxibs 
(celecoxib, rofecoxib) was reported by 4.5% (20 of 446) of the athletes. A total of 19.2% 
(42 of 219) of the prescribed NSAID users reported drug related adverse effects. 
Adverse effects were reported by 28.3% (17 of 60) of the acetic acid derivative users 
and by 14.4% (18 of 125) of propionic acid derivative users, whereas only 5.0% (1 of 
20) of the coxib users had adverse effects (Table 8). Adverse effects related to the 
central nervous system were reported by 11.0% (24 of 219) of the NSAID users and 
gastrointestinal adverse reactions by 8.7% (19 of 219) of the athletes. 
Antiasthmatic medication 
Any antiasthmatic medication used during the previous seven days was reported by 
7.0% (31 of 446) and 2.3% (20 of 1503) of the athletes and controls, respectively. 
Female athletes reported antiasthmatic medication more often than male athletes [11.4% 
(21 of 185) vs. 3.8% (10 of 261)]. After adjusting for age and sex, the OR for any 
reported antiasthmatic medication used during previous seven days was significantly 
higher among athletes compared with the controls (OR, 3.42; 95% CI, 2.05-5.70). Of the 
athletes having physician-diagnosed asthma, 56.5% (35 of 62) reported NSAID use.  
Antibiotics
Use of oral antibiotics during the previous seven days was reported by 2.7% (12 of 446) 
and 1.3% (20 of 1503) of the athletes and controls, respectively. After adjusting for age 
and sex, the OR (95% CI) for use of antibiotics was 2.15 (1.03-4.45) in the athletes 
compared with the controls (Table 7). Of the athletes, 35.2% had used antibiotics during 
the  previous 12 months (38.9% of the females and  33.0% of the males). 
Antiallergic medication 
Athletes reported use of any antiallergic medication during previous seven days 
significantly more often than the controls (12.6% vs. 6.0%; OR, 2.42; 95% CI, 1.69-3.46).  
After adjusting for age, sex and smoking, the OR for use of any antiallergic medication 
was significantly higher among endurance athletes compared with the controls (Table 7). 
Oral antihistamines were the most commonly used antiallergic medicines in all study 
groups, followed by intranasal corticosteroids.  
Other 
Current use of psychopharmaceuticals (antipsychotics, anxiolytics or antidepressants) 
was reported by 0.4% (2 of 446) and 3.4% (51 of 1503) of the athletes and controls, 
respectively (P = 0.001). Any anti-diabetic medication was used by 0.2% (1 of 446) of the 
athletes and 1.0% (15 of 1503) of the controls. All of these subjects used insulin. In 
40
41
addition to insulin, three control subjects also used oral anti-diabetic medication. Use of 
oral muscle relaxants was reported by 3.6% (16 of 446) and 1.5% (23 of 1503) of the 
athletes and controls, respectively.  
Prevalence of physician-diagnosed asthma and use of antiasthmatic  
medication (Study II) 
Physician-diagnosed asthma was more common in athletes as compared with controls 
(13.9% vs. 8.4%; Table 9). After adjusting for age, sex and smoking, OR (95% CI) for 
physician-diagnosed asthma was significantly higher among endurance and team sport 
athletes as compared with controls (Table 10). After adjusting for age, sex and smoking, 
the prevalence of asthma did not differ significantly between winter and summer athletes 
(OR, 1.60; 95% CI, 0.89-2.85). Of the asthma-like symptoms the occurrence of 
wheezing varied significantly (P = 0.004) by type of sport and was most often reported 
by endurance athletes.  
Use of any antiasthmatic medication during the last 12 months was reported by 9.6% of 
the athletes and by 4.2% of the controls. No difference was observed in the frequency of 
antiasthmatic medication used by winter or summer sport athletes (10.0% vs. 9.4%). 
After adjusting for age, sex and smoking, odds ratio OR (95% CI) for use of any asthma 
medication was 0.69 (0.17-2.92) for motor skills demanding events, 1.87 (0.85-4.11) for 
speed and power sports, 3.00 (1.68-5.37) for team sports, and 4.16 (2.22-7.78) for 
endurance events as compared with controls. None of the athletes used antiasthmatic 
medication without physician diagnosis. 
Inhaled β2-agonists were the most commonly used antiasthmatic medicines in all athlete 
groups. Inhaled β2-agonist use was reported by 7.4% (33 of 446) of the athletes and 
3.0% (45 of 1504) of the control subjects (Table 9). Long-acting β2-agonists (salmeterol, 
formoterol) were reported by 2.7% and 0.3% and short-acting β2-agonists (salbutamol, 
terbutaline) by 6.3% and 2.9% of the athletes and control subjects, respectively. Of the 
athletes 4.0% (18 of 446) reported using inhaled β2-agonists on a regular basis and 3.4% 
occasionally or when needed. A total of three athletes reported regular use of inhaled β2-
agonists without inhaled corticosteroid medication.  Similarly, inhaled corticosteroids 
were reported by 6.3% (28 of 446) and 1.9% (28 of 1504), cromons by 1.6% (7 of 446) 
and 0.2% (3 of 1 504), and leukotriene antagonists by 0.7% (3 of 446) and 0% of the 
athletes and control subjects, respectively. Of the athletes 5.4% used inhaled 
corticosteroids on a regular basis and 0.9% when needed. None of the athletes used 
antiasthmatic medication without having reported physician diagnosed asthma. Age, sex 
and smoking adjusted OR's (95% CI's) for use of inhaled β2-agonists and inhaled 
corticosteroids are represented in Table 10.   
Nineteen (30%) of those athletes having physician diagnosed asthma reported not using 
asthma medication at all. Of the control subjects having physician-diagnosed asthma 63 
(50%) reported not using asthma medication at all. As adjusted for age, sex and 
smoking, the difference was not statistically significant (P=0.09). 
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Allergies and pharmacological management (Study III) 
No statistical difference was found in the occurrence of a disturbing allergy (32.1% vs. 
30.1%), or in the age- and sex-adjusted OR between athletes and controls (OR, 1.12; 
95% CI, 0.89-1.41). A physician-diagnosed AR was reported by 26.5% (118 of 446) of 
the athletes and by 20.2% (303 of 1503) of the controls (Table 6). After adjusting for age 
and sex, the OR (95% CI) for physician diagnosed AR was significantly higher among 
endurance athletes as compared with controls (OR 2.24; 95% CI 1.48-3.39).  
The athletes reported the use of antiallergic medication significantly more often than the 
controls did (20.0% vs. 15.6%; OR, 1.42; 95% CI, 1.08-1.87).  Of the athletes 4.9% (34 
of 446) and 2.3% (34 of 1503) of the controls reported using antiallergic medication 
regularly. The adjusted OR (95%CI) for the use of any antiallergic medication was 
significantly higher among endurance athletes as compared with controls [2.79; (1.82-
4.28)]. No significant difference existed between winter and summer sport athletes in AR 
or use of medication. 
Allergic conjunctivitis was reported by 3.6% of the athletes and 5.6% of the controls. The 
women -both the athletes and controls- reported this condition more often than the men 
(Table 9). In both groups, the women used antiallergic eye drops more often than men 
did. 
The most commonly used antiallergic medicines in all study groups were oral 
antihistamines, followed by intranasal corticosteroids. A significant difference was 
observed in the frequency of oral antihistamine use between different sport events, with 
the endurance athletes reporting treatment most often. The adjusted OR (95% CI) for the 
use of oral antihistamines was significantly higher among endurance athletes as 
compared with controls [2.52; (1.54-4.12)].  
Among those with a history of any allergy, no significant difference in the prevalence of 
use of antiallergic medication was found between various groups of athletes and the 
general population. A total of 55.1% (65 of 118) of those athletes and 53.5% (162 of 303) 
of the controls having physician-diagnosed rhinitis reported using antiallergic medication. 
Female athletes with physician diagnosed AR used antiallergic medication more often 
than male athletes [65.3% (32 of 49) vs. 47.8% (33 of 69)]. Of the athletes reporting AR, 
34.7% (41 of 118) had also physician diagnosed asthma. Whereas, 6.4% (21 of 328) of 
those athletes who did not report AR, had asthma.  
Attitudes towards banned substances in sport (Study IV) 
Of the athletes 90.3% believed that it is possible to enhance exercise performance with 
the help of banned substances. A total of 70% believed that banned substances can 
enhance exercise performance substantially. A total of 30.8% of the athletes in motor 
skills demanding events believed that banned substances have no performance-
enhancing effects whereas only 2% of the endurance athletes thought so. According to 
the athletes, anabolic steroids were the most effective category of banned substances 
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followed by blood doping, peptide hormones and stimulants. A total of 73% of all the 
athletes believed that it is possible to improve sports performance with the help of 
anabolic steroids. 
Of the athletes, 30% knew another athlete using banned drugs to boost performance 
(Table 11). The figure was 42.5% among those practising sports that stress power and 
speed and 37.0% among endurance athletes. Lowest reported prevalence (17.8%) was 
among those in motor skills demanding events. Men knew doping users significantly 
more often than women (35.2% vs. 22.7%; P = 0.0044). One third of the athletes in 
speed and power sports knew someone using stimulants (Figure 1). Of the endurance 
athletes 18.5% personally knew someone using blood doping.  
None of the athletes admitted ever using banned substances. However, a total of 13.2% 
(59 of 446) of the athletes admitted they have used caffeine, pseudoephedrine or 
ephedrine at least once in life. Twenty of these athletes stated that they have used 
caffeine and/or pseudoephedrine containing products to treat their allergies or common 
colds. Of the athletes knowing another athlete using banned substances, 28.4% (38 of 
134) had used stimulants by themselves compared with 6.7% (21of 302) of those who 
reported not to know users (P < 0.001). Recreational drugs (cannabis, ecstasy, 
amphetamines, cocaine) were never used by 91.5% (408 of 446) of the athletes. A total 
of 7.6% (34 of 446) of the athletes had used cannabis 1-5 times in their life and 
additional 0.4% (2 of 446) over six times.   
TABLE 11. Athletes’ knowledge of the use of banned substances. 
Type of sport 
Personally knows 
an athlete using 
banned substances 
Banned substances 
has been offered to 
the athlete 
Suspects, that an 
athlete of his sport 
is using banned 
substances, but is 
not sure 
Knows personally an 
athlete of the same 
sport event using 
banned substances 
Speed and power 42.5%  21.2%  7.3% 4.6% 
Endurance 37.0%  10.2%  6.5% 4.6% 
Motor skills 
demanding 
events 
17.8%  13.7%  5.4% 1.4% 
Team  21.7% * 13.8%  5.3% 2.6% 
All athletes 30.0% (134 of 446) 14.8% (66 of 446) 6.1% (15 of 443) 3.4% (27 of 443) 
 *p<0.001 between subgroups 
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Figure 1. Percentage of the athletes by type of sport knowing an athlete who uses  
banned stimulants, anabolic steroids, peptide hormones or blood doping (N=446).
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DISCUSSION 
Validity of the data 
The response rate of the study exceeded 90% for the athletes, and was over 80% for the 
control subjects representing Finnish people of the same age. The studied outcome 
variables, prevalences of asthma and allergies and use of physician-prescribed 
medication, were based on previously used questions by the National Public Health 
Institute. In order to have comparable data on both the athletes and control subjects, only 
physician-prescribed medications were used in the analysis to avoid the random use of 
single over-the-counter tablets. Indeed, Paulose-Ram et al. (2003) showed that the 
majority of American adults who use non-prescription NSAIDs take them infrequently. 
Among non-prescription ibuprofen users, the median days of use per month was 
approximately 3 days.  
Asthma and antiasthmatic medication 
The current study of athletes was based on a self-administered questionnaire while 
corresponding data on control subjects were obtained through face-to-face interview. 
Interview data on specific medication for bronchial asthma cannot be accurate if the 
patient misunderstands or forgets either the indication or the nature of the treatment or 
is unwilling to report it. As the diagnosis of asthma is conceptually clear, however, its 
diagnosis is easily communicated by the doctor to the patient. It has been shown to be 
accurately verified by an interview (Heliövaara et al. 1993). The Mini-Finland Health 
Survey (Heliövaara et al. 1993), where our questions regarding asthma were adapted 
from, showed a good agreement in asthma between a clinical examination by physician, 
a home interview by public health nurse and the same questions of a self-administered 
questionnaire as were used in the current study (data not shown). No considerable 
doubt remains that this also concerns survey data on antiasthmatic medication. 
Use of pulmonary function tests for all athletes and controls would have provided 
increased information. However, introducing the new IOC regulations (including 
eucapnic hyperventilation test, metacholine challenge test, exercise challenge test, and 
bronchodilatation test) would have required nearly 8 000 pulmonary function tests in the 
present study. Previously, Lumme et al. (2003) and Helenius et al. (1998a) have shown 
that highly-trained athletes with physician diagnosed asthma nearly always show also 
increased bronchial responsiveness and eosinophilic airway inflammation. In fact, 
occurrence of asthma based on pulmonary function testing has been much higher in 
these studies than occurrence of physician-diagnosed asthma as reported by the 
athletes. 
A total of 4.2% of the control subjects reported use of asthma medication, which is a 
similar prevalence rate as recently reported among the Finnish general population 
(Haahtela et al. 2001). In all athlete groups, participants were dedicated athletes as 
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indicated by their training amount. The athletes represented the highest level of sports in 
Finland. Distribution of men and women as well as the number of daily smokers and 
non-smoker were not exactly the same between athlete and control groups. However, 
these confounding factors were adjusted using logistic regression models.  
Allergy and antiallergic medication 
In the present study, 20% of the control population reported having a physician-
diagnosed AR. This corresponds well with a previous study in our country. According to 
Vartiainen et al. (2002), a lifetime history of hay fever was reported by 21.9% of the 
random sample population of 25-54-year old subjects living in North Karelia, Finland. 
Use of skin prick testing for all athletes and controls would have increased obtained 
information. However, this would have required nearly 2000 skin prick tests in the 
present study. Previously, Helenius et al. (1997, 1998a) have shown that the occurrence 
of atopic allergy according to skin prick tests is much higher than self-reported physician 
diagnosed allergic rhinitis. In addition, clinical pollen allergy (positive skin test to pollen 
allergens and symptoms of allergic rhinoconjunctivitis) coincides extremely well with self-
reported physician diagnosed allergic rhinitis (Helenius et al.1997, 1998a). 
Most of the winter sport athletes represent Caucasian white population. In addition, the 
athletes practice and compete mostly in the same locations all year around in order to be 
able to do training on snow. The results obtained here for winter sport athletes are well 
generalized to all winter sport athletes. However, summer sport athletes represent a 
more culturally and ethnically diverse population. Thus, the results of summer sport 
athletes obtained here should be generalized with caution. It can be argued that these 
athletes live in the health system that enhances the identification of allergic rhinitis and 
subsequent treatment. However, both controls and athletes live in a similar society. In 
addition, the prevalence of allergic rhinitis was very similar between controls and athletes 
in other than endurance events.
Use of physician-prescribed medication 
During collection of urine samples for doping control purposes, the athletes are asked to 
report all the prescribed medicines and over-the-counter medications they have used in 
the previous seven days. Thus, athletes should be aware of the medications they use 
and be able to report them accurately. Self-reports may result in underestimation of the 
actual usage. We believe, however, that in elite athletes the bias should be small 
because the medications reported are not classified as doping substances.  
The athletes may have been more familiar with their medications than were the controls 
and thus would have reported them more accurately. However, the questionnaire 
requested only to the medications used, which required no detailed knowledge of these 
medications. Thus, detailed knowledge of these medicines would probably not have 
affected the required data substantially. 
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In Finland, all antiasthmatic medicines and oral antibiotics can be acquired only by 
prescription. Some NSAIDs and antiallergic medicines are on restricted sale to the 
public, but most have a prescription only medicine licence. In order to have comparable 
data on both the athletes and control subjects, only physician-prescribed medications 
were used in the analysis to avoid the random use of single over-the-counter tablets. 
Attitudes towards doping 
Because of self-reported questionnaires and limited comparable data it is hard to 
evaluate how reliable are the results covering a prohibited practice. Thus, these findings 
should be interpreted with caution. Research work based on questionnaires covering a 
prohibited practice has limits: answers may be intentionally false as the subjects 
questioned may not wish to reveal that they or their team mates use drugs, even if 
anonymity and confidentiality are guaranteed by the investigators. According to Laure 
and Reinsberger (1995) some substances such as cannabis, cocaine, or narcotic 
analgesics although banned or controlled, are not considered as doping by athletes. 
Moreover, some substances are prohibited only in-competition e.g. ephedrine. 
The present study was conducted a year – a year and a half after the Nordic Skiing 
World Championships in Lahti. One might expect that doping cases of the Finnish skiers 
in Lahti has some impact on the present results. Because the athletes were asked 
whether they personally knew some athlete using banned substances, the authors 
believe that the possible bias is small and limited mostly to winter sport events and 
especially to cross-country skiing.   
Comparison with previous findings 
   
Use of physician-prescribed medication 
Increased frequencies of allergies, asthma, and stress injuries have been reported in 
highly trained athletes compared with the general population (Kujala et al. 1995a; 
Helenius et al. 1997 and 1998a; Nystad et al. 2000; Adirim and Cheng 2003). Athletes 
and sports medicine physicians try to optimize the treatment of symptoms related to 
extreme training (such as irritation of airways) during their active elite career, but most of 
the athletes may not need these medications after their active careers. Indeed, Helenius 
et al. (2002) observed in a 5-year follow-up that occurrence of athletes’ asthma and use 
of antiasthmatic medication decreased substantially when elite athletes finished active 
training. Whether the use of NSAIDs decreases similarly remains unclear. 
Apart from few studies reporting of the use of antiasthmatic medication in elite athletes, 
there are only three previously published studies of the use of medications in elite level 
athletes. None of these has included control group of the general population. Recently, 
Huang et al. (2006) reported of the use of medications by Canadian athletes at Atlanta 
(N=257) and Sydney (N=300) Olympic Games. Overall use of medications was reported 
by 61% and 54% of the athletes in Atlanta and Sydney, respectively. NSAIDs were used 
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by 33% of the athletes in Atlanta and by 38% of those in Sydney. Although the usage of 
NSAIDs was higher in Sydney, the overall use of medications was slightly decreased 
(61% vs. 54%). The use of NSAIDs was highest in softball (60%) in Atlanta and 
gymnastics (100%) in Sydney. The authors reported the prevalence of use only for 
those sports that had the highest rate of NSAID use. Surprisingly, Huang et al. do not 
report antiasthmatic and antiallergic medications separately from other medications. Use 
of antiallergic medication is reported together with systemic anti-infectives (15.6% of the 
athletes in Atlanta and 7.0% in Sydney) and antiasthmatic medication is included into 
the category other medications. Because the authors do not specify whether the 
interviews were carried out before, at, or after the Olympics and what was the time 
period for the use of medications that the authors were interested in, the comparison 
with the present study is limited.  
Berglund and Sundgot-Borgen (2001) evaluated the use of NSAIDs and inhaled β2-
agonists in Swedish Olympic athletes in connection with the Olympic Games in 1996, 
1998, and 2000. Two to 4 weeks before the games all male and female athletes at the 
summer Olympic Games 1996 in Atlanta (N=183), 2000 in Sydney (N=157) and winter 
Olympics 1998 in Nagano (N=105) were interviewed. The percentage of athletes using 
NSAIDs decreased by one-third from the Atlanta games (11.5%) to the Sydney games 
(7.6%). The corresponding value in Nagano was 6.7%. The authors estimated that use 
of NSAIDs is approximately 6-10 times higher in Swedish Olympic athletes than in the 
general population of the same age. The result is, however, based on rough estimates 
and the significance of the data can be considered only as speculative. Between the 
summer games in 1996 and 2000 the use of inhaled β2-agonists decreased significantly 
by 44% from a prevalence of 11.5% down to 6.4%. In Nagano, the prevalence of inhaled 
β2-agonists use was 15.2%. The use of inhaled β2-agonists was similar in men as 
compared with women at all three Olympic Games studied. A major contributing factor 
to the high prevalence of inhaled β2-agonist use in Nagano was the large group of cross-
country skiers with high prevalence of EIA. The authors discussed that the decrease in 
inhaled β2-agonist use is most likely multi-factorial. The trend to consider EIA as an 
inflammatory disease has changed basal treatment. Also a national anti-doping policy 
demanding better medical investigations to allow use have limited the unnecessary use 
of inhaled β2-agonists.
Corrigan and Kazlauskas (2003) reported of the medication use in Athletes selected for 
doping control at the Sydney Olympics. All the athletes selected for the doping test were 
asked “what medications have you taken in the past three days?” A total of 25.6% of the 
athletes reported of the NSAID use.  Inappropriately high doses and concomitant use of 
several different NSAIDs on the same day were found to be problems associated with 
NSAID use.  It has been observed that concurrent use of more than one NSAID 
increases the upper gastrointestinal bleeding strikingly (Lewis et al. 2002). The same 
authors reported that also striking dose-response relationships were seen with four to 
eight-fold increases in the risk for gastrointestinal bleeding even with conventionally 
used dose ranges.  Corrigan and Kazlauskas (2003) concluded that a dangerous 
overuse of NSAIDs in the athletes together with multiple medicine use emphasizes the 
dangers of drug interactions.  In the present study, only three athletes had used more 
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than one NSAID during the previous seven days of the study and none reported using 
very high doses. 
Kujala et al. (2003) reported that the need for long-term medications for cardiac disease 
and asthma, as well as the use of NSAIDs and antacids, is reduced among Finnish 
former top-level athletes. However, old sport records have been broken and the training 
of elite athletes has changed over time. It may be that nowadays the regular training in 
recreational sports is similar, in many respects, to the way former top athletes trained. 
There are no previous reports of the prevalence of use of oral antibiotics in athlete 
populations. It seems that when infections develop, even though most are of viral origin, 
some athletes and physicians will cover with antibiotics just in case. Although heavy 
training predisposes to viral and possibly to bacterial infections (Nieman 2000), the use 
of oral antibiotics seems quite liberal. Speed and power athletes used oral antibiotics 
four times more often than controls. Too liberal use of antibiotics should be avoided due 
to antibiotic resistance. Adverse effects such as gastrointestinal upset are common, and 
may affect an athlete’s performance (Ciocca 2005). Also tendon injuries have been 
reported after treatment with fluoroquinolones (Khaliq and Zhanel 2003). A large 
proportion of these antibiotics were prescribed for respiratory tract infections; whether 
these medications were prescribed for bacterial infections needs to be further assessed.  
Multiple drug use predisposes athletes to drug interactions. NSAIDs are the most 
frequently used group of medications in athletes and their interactions with other drugs 
are common. Medications known to increase the risk of COX-2-related adverse events 
include diuretics, ACE inhibitors, warfarin, corticosteroids and NSAIDs (Verrico et al. 
2003). Over half of the athletes having physician-diagnosed asthma reported using 
NSAIDs. NSAIDs can cause or increase the incidences bronchospasm, hypersensitivity 
reactions, angioedema, urticaria, rhinitis and life-threatening anaphylactic reactions and 
should be used with caution in asthmatics (Szczeklik 1977).
All medications have adverse effects that may have deleterious effects on elite athletes’ 
maximal exercise performance. Thus, any unnecessary medication use should be 
minimized in elite athletes. If athletes learn to treat all minor illnesses such as common 
colds with antibiotics, they may also continue their habits after their sports careers. Elite 
athletes are also role models for young athletes, which should also be taken into 
consideration when medications are used. 
NSAIDs are cornerstone medications in the treatment of soft-tissue injuries (Corrigan 
and Kazlauskas 2003), however their use may have serious gastrointestinal adverse 
effects (Shoor 2002). The frequency of acute injuries varies among different sporting 
events and each sport has a specific injury profile (Kujala et al. 1995). This could partly 
explain the differences in NSAID use among various sporting events, as noted in this 
study.
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Prevalence of physician-diagnosed asthma and use of antiasthmatic medication 
   
In a recent study, Nystad and co-workers (2000) reported the prevalence of asthma in a 
large sample of Norwegian national level athletes (N = 1082) compared with general 
population (N = 1038). However, the questions concerning asthma were only part of a 
more extensive questionnaire and authors do not specify used medications. Actual 
response rate in asthma study was only 67% (62% for the controls) and results were 
not compared between winter and summer sport events. No study has reported the 
prevalence of asthma and use of asthma medication among elite athletes after IOC 
restricted the use of inhaled β2-agonists in 2002. 
Helenius and Haahtela (2000) studied 253 Finnish summer sport athletes using a similar 
questionnaire to that used in the present study. Use of antiasthmatic medication was 
reported by 10% of the speed and power athletes, by 22% of the long-distance runners, 
and by 21% of the swimmers studied. Most commonly used medication was inhaled β2-
agonists. These figures are significantly higher than those reported in the present study, 
in which 9% of all athletes reported use of any antiasthmatic medication. The frequencies 
for use of inhaled β2-agonists and inhaled corticosteroid were even lower. In accordance 
with the study of Helenius et al. (2000) use of antiasthmatic medication was most 
frequent in endurance athletes. However, the present study included all the athlete 
groups financially supported by the National Olympic Committee. The occurrence of 
asthma medication use was significantly lower among athletes in motor-skills demanding 
events as compared with other sport groups (2.7% vs. 14.8% among endurance 
athletes). This lowers somewhat the occurrence of asthma medication use in the whole 
athlete group. It can also be argued that self-selection may have happened so that 
asthmatic athletes could not achieve the highest athletic level, which then would lower 
the occurrences for asthma and antiasthmatic in these groups. However, Potts studied 
735 swimmers using respiratory-symptom questionnaire, and observed that occurrence 
of asthma was most common in the international-level swimmers group as compared 
with junior or national-level swimmers (1996).
Occurrence of asthma has been higher in winter than in summer sports athletes  (Fitch 
1984; Voy 1986; Weiler et al. 1986; Larsson et al. 1993; Sue-Chu 1996; Helenius et al. 
1997 and 1998a; Weiler et al. 1998 and 2000). Larsson et al. (1993) observed that 
asthma as defined by a positive methacholine challenge test and at least two exercise-
related symptoms affected 33% of cross-country skiers and 3% of the control subjects. If 
a previously diagnosed asthma was included in the analysis, this occurrence increased 
up to 55%. Of these athletes, 36% used antiasthmatic medication, which included most 
often inhaled β2-agonists, followed by inhaled corticosteroids, and chromoglycans. Sue-
Chu et al. (1996) investigated 118 cross-country skiers from Norway, and 53 from 
Sweden. Using similar definitions, asthma was found in 12% of the Norwegian and in 
42% of the Swedish skiers. Of them, 16% and 38%, respectively, reported use of 
inhaled β2-agonist, and 4% and 23% use of inhaled corticosteroids. In contrast with 
previous findings, no significant difference was observed in the frequency of asthma 
between winter and summer athletes. Females used significantly more often medication 
than did males. Occurrence of asthma has been higher in females than in males in 
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swimmers and also in other athlete groups (Helenius et al. 1998a; Potts 1996; Rundell 
et al. 2001). 
A few studies of elite athletes have included any reports of used antiasthmatic 
medication (Fitch 1984; Heir et al. 1994; Helenius et al. 1997; Weiler et al. 1998 and 
2000). However, these studies have included only winter or summer sport athletes and 
do not include representative control samples. No study has been specifically designed 
to compare occurrence of antiasthmatic medication between different sport events. 
Between 1994 and 2000 the use of asthma medication increased by 42% in Finnish 
general population (Haahtela et al. 2001). However, during the recent years use of 
asthma medication seems to have lowered in the Finnish athlete population (Helenius et 
al. 1997). In general population, the use of preventive medicines (inhaled 
corticosteroids) has grown more rapidly than symptom relieving, short acting β2-
agonists. Since 1994 the ratio of defined daily doses of preventers to those of relievers 
exceeded 1.0 (Haahtela et al. 2001). In contrast, inhaled β2-agonists are still most 
commonly used antiasthmatic medication, although eosinophilic and neutrophilic airway 
inflammation affects every fifth athlete (Helenius et al. 1998c; Karjalainen et al. 2000; 
Lumme et al. 2003). 
In the present study, no overuse of inhaled β2-agonists or antiasthmatic medication was 
found in Finnish Olympic athletes. The low occurrence of asthma in the present as 
compared with previous studies (Voy 1986; Larsson et al. 1994; Sue-Chu et al. 1996; 
Helenius et al. 1997 and 1998a; Weiler et al. 1998 and 2000; Langdeau et al. 2000) 
suggests that under-diagnosis may still exist in this athlete population. Since only two-
thirds of the asthmatics in this study used antiasthmatic medication under-treatment may 
also occur. Similarly, of the asthmatic controls 50% used antiasthmatic medication. 
However, their requirements for respiratory system during exercise performance are 
much less. 
   
Prevalence of physician-diagnosed allergies and their pharmacological management  
Helbling et al. (1990) surveyed 2961 elite Swiss athletes (response rate 70%) 
participating in 68 sports. A total of 16.8% of the athletes indicated that they had AR, and 
of these 59% needed medication during the pollen season. In the present study, 26.5% 
of the athletes reported AR with 55% having medication for it. 
Several epidemiologic studies have shown an association between AR and asthma 
(Leynaert et al. 2000). Guerra et al. (2002) reported, after controlling for age, sex, 
smoking, and atopic status, that rhinitis increased risk of asthma threefold. In the allergy 
report from the American Academy of Allergy, Asthma, and Immunology it was estimated 
that up to 38% of patients with AR have asthma (2000). In the present study 34.7% of 
the athletes with AR reported having asthma, while only 6.4% of the athletes not 
reporting AR had asthma. 
55
56
Helenius et al. (1998a) found that clinical pollen allergy (a positive skin-prick test (SPT) 
and symptoms of seasonal allergic rhinoconjunctivitis (ARC) affected one-third of the 
endurance athletes competing in summer events. Katelaris et al. (2003) determined the 
incidence of seasonal ARC in a large sample of Australian elite athletes (N = 977). Of 
these, 49.5% had symptoms of ARC, 23% a history of asthma, and 10% of eczema. A 
total of 56% had a positive SPT to at least one allergen tested and 34% to at least one 
seasonal allergen. Of the athletes, 25% met the criteria for a diagnosis of seasonal ARC 
(a positive SPT to at least one seasonal allergen and the presence of at least two 
symptoms of ARC). 
Maiolo et al. (2003) studied asthma and atopy in 1060 Italian athletes who were trying 
out for a position on the Italian Olympic Team for the Sydney 2000 Olympic Games. Of 
the studied athletes, 18.3% reported symptoms of atopy. No significant gender 
differences were observed. A total of 14.5% of the athletes reported being diagnosed for 
AR (15.5% of the males and 12.3% of the females). Symptoms of rhinitis were more 
frequent in the subgroup of endurance athletes than in the other groups. These findings 
correspond well with our results and can be explained by the athletes’ increased 
exposure to airborne allergens especially in endurance events (Helenius et al. 1998a). In 
contrast, the prevalence of allergic conjunctivitis did not differ between athletes and 
controls in the present study. This could be explained by the fact that athletes’ 
conjunctivas do not receive such an increase of airborne allergens as airway mucosal 
lining membrane does. 
Attitudes towards doping 
Because of different legislation, cultural differences, and different methods employed it 
is difficult to compare present findings with the previous studies e.g. The Dubin 
Commission in Canada some 15 years ago (Dubin 1990). During the government 
hearings, current and former athletes have supported the notion that there is a 
significant doping problem.   
Recently, Waddington et al. (2005) reported that 6% of the English professional football 
players indicated that they personally knew players who used performance-enhancing 
drugs, and 45% of the players knew players who used recreational drugs (Waddington 
et al. 2005). Laure et al. (2004) reported that of the French high school athletes 4% had 
taken doping agents (cannabis, alcohol and ecstasy excluded) at least once in life and 
19% stated that they had used cannabis at least once in the previous two months. 
Similarly 3.4% of the athletes in the present study reported that they personally knew 
another athlete in their own sport who uses banned substances. However, 30% of the 
athletes reported that they personally knew another athlete who uses substances. 
Because the difference is nearly ten-fold between these two questions it should be 
noted that it is possible that different respondents could have been referring to the same 
drug using athlete(s).  This survey does not give an answer whether these referred 
athletes were from other events than those financially sponsored by National Olympic 
Committee or were athletes competing on lower level. Recreational drug use seems to 
be less serious problem among Finnish elite athletes than in English professional 
56
57
football or among French high school athletes. Only 8.5% of the Finnish elite athletes 
reported life-time use of cannabis, cocaine ecstasy or amphetamine. Drug use in sport 
cannot, however, be isolated from the wider society of which sport is a part. The extent 
of life-time prevalence of recreational drug use among young adults (15-34 years) in the 
Finnish general population is substantially lower than in most Western European 
countries (EMCDDA 2004). Life-time use of cannabis is two to three times more 
common among young Finnish general population than among elite athletes.  
Bents et al. (2004) made a small (N=122) survey to assess the use of stimulants among 
collegiate hockey players in the USA. More than half of the players reported past or 
present use of stimulants and almost half (46%) reported pseudoephedrine use to 
enhance performance. Over 33% stated they would use a banned substance if it would 
help them to get to the National Hockey League. A total of 59 athletes in the present 
study reported of the past or present use of caffeine, pseudoephedrine or ephedrine. 
Twenty of these stated that they have used caffeine and/or pseudoephedrine containing 
products to treat their allergies or common colds. None of the athletes admitted ever 
using banned substances. However, a total of 13.2% of the athletes admitted they have 
used stimulants at least once in life. This demonstrates that stimulants are being used 
by some athletes and that athletes do not consider stimulants as doping because their 
use out-of-competitions is not banned. Green et al. (2001) reported that although 
ephedrine may be considered as a recreational drug, one-half of those college athletes 
admitting use of ephedrine consumed it to increase performance. 
Over 90% of the athletes thought exercise performance can be improved by using 
banned substances. However, the vast majority of the athletes were not in favour of 
doping. Almost all the athletes (96.9%) believed that it is possible to make to the 
international top in their sport without doping. In contrast with this, Laure et al. (2004) 
reported that even 21% of the French high school athletes thought that refusing to use 
doping means losing all chances of becoming a great champion. Most of the athletes 
believed that use of banned substances has serious adverse effects and only 7.3% of 
athletes reported that they would start using presently banned substances if they were 
allowed some day.  
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SUMMARY 
The present study aimed at determining the use of physician-prescribed medication and 
factors associated with it in a large number of elite athletes compared with a 
representative control sample of the general population. Of all the athletes (N = 494) 
financially supported by the National Olympic Committee, 446 completed a structured 
questionnaire (response rate 90.3%) in 2002. A control group (N = 1503, response rate 
80.1%) comprised an age-matched sample from the population-based study collected 
by the National Public Health Institute.  
Elite athletes use significantly more frequently antiasthmatic and antiallergic 
medications, NSAIDs, and oral antibiotics than the general population. All these 
medicines have potential adverse effects that may have deleterious impact on the 
maximum exercise performance of elite athletes. The immediate and long-term adverse 
effects of the use of medications should be taken into account.   
The frequency of reported antiasthmatic medication is clearly lower than the reported 
occurrence of physician diagnosed asthma in a large sample of Finnish Olympic 
athletes. Use of asthma medication is most frequent in endurance athletes, but no 
difference is observed between winter and summer sport athletes. Female athletes use 
antiasthmatic medication more often than males. No evidence of overuse of inhaled β2-
agonists is found. Treatment of airway inflammation seems unsatisfactory. 
Endurance athletes have physician-diagnosed AR and they use antiallergic medication 
more often than athletes in other events or control subjects. Female athletes use 
antiallergic medication more frequently than male athletes. Only half of those athletes 
reporting AR take antiallergic medication. More attention thus needs to be paid to the 
optimal management of allergic rhinitis in highly-trained athletes. 
The vast majority of the athletes are not in favour of doping and nearly all of the athletes 
believe that it is possible to make to the international top in their sport without doping. 
However, athletes in different sports have different approach to doping. To know an 
athlete using banned substances seems to increase risk to use stimulants. Risk of 
doping appears to be highest in speed and power sports and lowest in motor skills 
demanding sports.
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CONCLUSIONS
1. The use of physician-prescribed antiasthmatic and antiallergic medications, 
NSAIDs, and oral antibiotics during the past seven days was 2-4-fold in elite 
athletes compared with the general population of the same age. Antiallergic 
medication was most commonly used medication group among athletes followed 
by NSAIDs, antiasthmatic medication and oral antibiotics.  
Physician-diagnosed asthma was significantly more common in athletes (13.9%) 
than in control population (8.4%). Endurance athletes reported asthma most often 
followed by team sport athletes. Surprisingly, no difference was observed in the 
prevalence of asthma between winter and summer sport athletes. 
Physician-diagnosed allergic rhinitis was significantly more common among 
endurance athletes (36.1%) as compared with other events (23.4%) or control 
subjects (20.2%). No difference in the prevalence was observed between other 
events and controls. 
2. Type of sport had significant impact on medication use. Speed and power sport 
athletes used NSAIDs and oral antibiotics most often. Endurance athletes 
reported use of antiasthmatic and antiallergic medication most often. 
3. Every fifth athlete reported of the adverse effects associated with the use of non-
steroidal anti-inflammatory drugs. Nearly half of the athletes using indomethacin 
had experienced some drug related adverse effects. 
4. Majority of the athletes were not in favour of doping. Although most of the 
athletes believed that it is possible to improve athletic performance by using 
banned performance-enhancing substances, nearly all athletes believed that it is 
possible to make to the international top in their sport without doping. 
Three out of ten athletes reported that they personally knew some athlete using 
banned substances and 15% reported that banned substances have been offered 
to them. Athletes in different sports have different approach to doping. To know 
an athlete using banned substances seems to increase risk to use stimulants. 
Risk of doping appears to be highest in speed and power sports and lowest in 
motor skills demanding sports.  
Clinical and practical implications  
Only half of those athletes reporting allergic rhinitis take antiallergic medication. Thus, 
under-treatment may be a problem for elite athletes. More attention thus needs to be 
paid to the optimal management of allergic rhinitis. Untreated allergic rhinitis may 
decrease athletic performance and compromise the treatment of asthma. 
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All the abovementioned medicines have potential adverse effects that may have 
deleterious impact on the maximum exercise performance of elite athletes. Thus, any 
unnecessary medicine use should be minimized in elite athletes. If athletes learn to treat 
all minor illnesses such as common colds with antibiotics, they may also continue their 
habits after their sports careers. Too liberal use of antibiotics should be avoided due to 
antibiotic resistance and possible adverse effects. Antibiotics should be used only for 
confirmed respiratory infections of bacterial origin. 
Health promotion and anti-doping activities can be better focused if the counselors have 
more detailed information about the attitudes of defined subgroups of sport. Successful 
interventions should be used as examples when new prevention methods are planned. 
Sport associations should repeatedly monitor not only the use of banned substances but 
also the trends of use of legal medications in athletes. More profound study of the 
attitudes and beliefs leading to ample use of legal medications in athletes is an 
interesting area of future research.  
Physicians in sports medicine, athletes, coaches, and also pharmacists should be better 
counseled of the adverse effects of commonly used medications in athletes and their 
specific effects on athletes (e.g. tissue level effects of the NSAIDs and coxibs) and 
exercise performance.  Experts in the field of sports-pharmacy are needed to consultate 
athletes and coaches of the rational use of medicines. 
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